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General introduction 
8 Chapter 1
This doctoral thesis describes cardiovascular and metabolic risk factors in children en young 
adults with a small birth size, either due to being born small for gestational age (SGA) or due to 
prematurity. For those born SGA with persistent short stature, the short and long-term effects 
of growth hormone (GH) treatment on these risk factors were studied. This chapter provides 
definitions and gives background information on SGA and prematurity. Finally, the aims of the 
study, the outline of this thesis, inclusion and exclusion criteria and study design of the IUGR-1, 
IUGR-2 and IUGR-3 study (Appendix A-C), and the PROGRAM/PREMS study (Appendix D) are 
presented. 
PART 1 SMALL FOR GESTATIONAL AGE
 
1.1 Definition
In order to determine whether a child is born SGA the following is required: 1) an accurate 
knowledge of gestational age, 2) accurate measurements of weight and length at birth, and 3) 
an appropriate reference population in order to determine a standard deviation score (SDS) for 
birth weight and/or birth length (1). In 2001, the International SGA Advisory Board Panel reached 
consensus on the definition of SGA, by defining SGA as a birth length and/or birth weight below 
-2 SDS, adjusted for gestational age and gender (2). 
 The term SGA is used to define size at birth and does not refer to intra-uterine growth. Intra-
uterine growth describes the growth velocity in fetal life, which is determined by at least two 
ultrasound measurements during pregnancy. The term intrauterine growth retardation (IUGR) 
is used when a fetus suffers from reduced fetal growth. A child born SGA has not necessarily 
suffered from IUGR, but may have been small from the beginning of fetal life. On the other hand, 
a child with IUGR late in gestation can have a normal size at birth. These different fetal growth 
patterns are shown in Figure 1. Because the intrauterine growth is often unknown, we nowadays 
prefer to use the term SGA for neonates with a birth size below -2 SDS. 
1.2 Prevalence and aetiology 
By definition, approximately 2.3% of all live-born neonates are born SGA. In 2007, 181.336 infants 
were live-born in the Netherlands (Central Bureau of Statistics, Voorburg, the Netherlands). 
According to the definition, 4171 of them were born SGA.
 The etiology of SGA is multifactorial, including fetal, maternal, placental, and demographic 
factors (3-5). Identification of the underlying cause of SGA birth is important, since it may have 
consequences for prognosis and treatment. It is, however, important to realize that the cause 
of SGA birth remains unidentified in 40% of all cases. Table 1 shows some of the many factors 
associated with SGA birth. 
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Figure 1. Fetal growth chart showing various intrauterine growth patterns.
LGA: large for gestational age, AGA: appropriate for gestational age, SGA: small for gestational age.
Table 1. Factors associated with SGA birth
Fetal factors
Chromosomal disorders Trisomy 21 (Down syndrome)
Trisomy 18 (Edward syndrome)
Monosomy X (Turner syndrome)
Trisomy 13 (Patau syndrome)
Genetic disorders Achondroplasia
Bloom syndrome
Inborn errors of metabolism
Congenital anomalies Cardiac abnormalities
Potter syndrome
Intrauterine infections TORCHES (Toxoplasmosis, Rubella, Cytomegalovirus, 
Herpes simplex, Syphilis)
Malaria
Trypanosomiasis
Human immunodeficiency virus (HIV)
Maternal factors
Medical conditions Acute or chronic hypertension
Pre-eclampsia
Renal disease
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Table 1. Factors associated with SGA birth (continued)
Maternal factors
Diabetes mellitus
Collagen vascular disease (e.g. systemic lupus 
erythematosus)
Antiphospholipid syndrome
Cyanotic heart disease
Chronic anemia
Chronic pulmonary disease
Abnormalities of the uterus
Environmental factors Maternal nutrition
Low pregnancy BMI 
Poor maternal weigt gain
Age at delivery (<16 or >35 years)
Low socioeconomic status
Cigarette smoking
Alcohol abuse
Therapeutic drugs (e.g. anticonvulsants, anticoagulants)
Use of illicit drugs
Placental factors
Structural abnormalities placenta
Reduced blood flow
Reduces area for exchange oxygen and nutrients Placental hematomas, infarcts or local lesions
Partial abruption
Demographic factors
Maternal and paternal height
Ethnicity
Parity Nulliparity
Grand multiparity
Multiple gestation
Previous delivery of SGA infants
High altitude
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2 Clinical and endocrine aspects associated with SGA birth
2.1 Short stature
SGA birth is a common cause of short stature in childhood and adulthood, accounting for 22% 
of all cases (6). Most children show spontaneous catch-up to a normal height above -2 SDS. 
However, 10-15% of short children born SGA do not show sufficient catch-up growth and remain 
small (7, 8). Catch-up growth is most pronounced during the first six months of life and is usually 
completed in the first two years of life. However, catch-up growth may take longer in prematurely 
born SGA children since prematurely born children differ from children born term with regard 
to several parameters. For example, distance between height SDS at two years of age and target 
height SDS and distance between height SDS at the age of two years and birth length SDS (9). The 
absolute difference in duration of gestation had no effect on the timing of catch-up growth (7,9). 
By the age of 8 years, 91% of children born SGA have spontaneously reached a height above -2 
SDS (9). 
2.2 The GH-IGF-IGFBP axis
Fetal and postnatal growth and development are regulated by complex metabolic and endocrine 
processes, which are under the influence of genetic and environmental factors. The GH-IGF-
IGFBP axis (Figure 2) plays a major role in this system. 
 The mechanisms underlying persistent short stature in children born SGA is still largely 
unknown, but disturbances in the GH-IGF-IGFBP axis may play a role. Many short SGA children 
show a reduced spontaneous GH secretion during a 24-hour GH-profile and/or low GH peaks 
during GH provocation tests (10-14). Serum IGF-I and IGFBP-3 levels are also lower in short SGA 
children than in healthy controls (15-17). 
2.2.1 Growth hormone (GH)
GH is secreted by the pituitary gland under the control of the hypothalamic hormones GH-
releasing hormone (GHRH) and somatostatin, as well as ghrelin, which is predominantly secreted 
by the stomach (18). GHRH and ghrelin bind to their receptors in the pituitary and stimulate GH 
secretion. Somatostatin inhibits GH release. Most of the anabolic actions of GH are mediated by 
IGF-I, but GH has also many cellular effects that are independent of IGF-I (19). 
2.2.2 Insulin-like growth factors (IGF)
The IGF system consists of IGF-I, IGF-II and insulin. They show structural similarity by sharing 
approximately 50% of their amino acids. The metabolic actions of insulin are mediated by binding 
to the insulin receptor. The growth-promoting effects of IGF-I and IGF-II are primarily mediated 
by binding to the IGF-I receptor. 
 Because of the strong homology between IGFs and insulin and between the insulin receptor 
and the IGF-I receptor, interactions between IGFs and the insulin receptor take place. The insulin-
like effects of IGF-I are only 5% of that of insulin, but in case of excess of free IGF-I, it is capable of 
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lowering glucose levels 50 times more than insulin alone. This is, however, prevented by binding 
of IGF-I to specific IGF binding proteins (IGFBPs) in the circulation. Approximately 0.4% to 2% 
of IGF-I levels circulate as free IGF-I or at least very dissociable IGF-I. Acute as well as long-
term biological effects of free IGF-I have been described, indicating that free IGF-I is the main 
biological active fraction (20). 
 IGF-I is a major regulator of growth and promotes proliferation, differentiation and cell 
survival. In addition, it promotes metabolic actions necessary for growth, such as protein 
synthesis, calcium accretion and fatty acid and glucose transport (21,22). Next to growth, IGFs 
are important in the development and function of the central nervous system, skeletal muscle 
and reproductive organs. The major source of circulating IGF-I is the liver, but it is also locally 
produced in various tissues (23). 
Figure 2. Physiology of the GH-IGF-IGFBP axis. Adapted from Holt (18).
2.2.3 IGF binding proteins
The majority of circulating IGF-I is bound to IGF binding proteins (IGFBPs), of which six classes 
have been identified. The majority of IGF-I (70-95%) is bound in a ternary complex with IGFBP-3 
and an acid-labile subunit (ALS) (24). IGFBP-3 and ALS are both regulated by GH. Functions of 
IGFBPs are summarized in Table 2. 
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Table 2. Functions of the insulin-like growth factor binding proteins
All IGFBPs Decrease bioavailability of free IGFs to bind to IGF 
receptors
IGFBP-1 and IGFBP-2 Prevent IGF-induced hypoglycaemia
IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-4 Regulate transport of IGFs between intravascular and 
extravascular spaces
IGFBP-3 Prolong the half-life of IGFs in the circulation
IGFBP-1, IGFBP-3 and IGFBP-5 Enhance actions of IGFs by forming a slow-releasing pool 
of IGFs
IGBBP-1 and IGFBP-3 Direct cellular effects via own IGFBP receptors
Adapted from Ferry et al (Horm Res 1999) and Collet-Solberg et al. (Endocrine 2000).
2.3 Cardiovascular disease and type 2 diabetes
2.3.1 Historical data and hypotheses
Epidemiological studies have shown that low birth weight is associated with the development of 
type 2 diabetes and associated disorders such as hypertension, dyslipidaemia and cardiovascular 
disease in adults (25-27). Insulin resistance plays an important role in the pathogenesis of these 
diseases (28,29), but the exact mechanism underlying these associations in still unknown. Several 
hypothesis have been proposed over time. 
 Fetal origins hypothesis: In 1989, Barker et al. were the first to postulate a hypothesis 
based on the inverse association found between birth weight and adult disease (30). They 
suggested that events leading to fetal malnutrition could result in permanent endocrine and 
metabolic changes in the fetus, called re-programming. At first, the fetus would benefit from 
these adaptations, as it would ensure to remain alive during fetal life, but on the long-term this 
re-programming might result in an increased risk of adult diseases. 
 Fetal insulin hypothesis: This hypothesis was formulated in 1999 by Hattersley et al. 
and states that the association between low birth weight and insulin resistance is principally 
genetically mediated (31). Insulin is an important intrauterine growth factor. Parental genes 
involved in insulin resistance, which are passed to the fetus, could result in both low-insulin-
mediated growth and in insulin resistance leading to type 2 diabetes in later life. 
 Growth acceleration hypothesis: In 2004, Singhal and Lucas suggested that not low birth 
weight per se, but rapid postnatal growth is responsible for the increased risk for adult diseases 
in later life (32). Almost every child is genetically determined to grow to their own growth 
potential. Children born SGA, thus below their genetic growth potential, show later postnatal 
growth. According to this hypothesis, this catch-up growth will lead to the development of adult 
diseases. 
 Fat accumulation hypothesis: Based on detailed measurements of body composition using 
Dual Energy X-ray Absorptiometry (DXA) absorptiometry, our research group further specified 
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the growth acceleration hypothesis (33). It was shown that not catch-up growth per se, but rapid 
fat accumulation results in an increased risk for adult diseases. This indicated that small size at 
birth followed by growth in height and weight as such is not a problem when it is accompanied 
by a normal amount of fat mass. Leunissen et al. also demonstrated that rapid weight gain, 
especially during the first three months of life, is a risk factor for higher body fat percentage and 
associated risk for cardiovascular disease in adulthood (34). 
2.3.2 Determinants of cardiovascular disease and type 2 diabetes
In order to determine the risks for cardiovascular disease and type 2 diabetes, various 
measurements and biomarkers were investigated in the studies described in this thesis. 
Body composition
Body composition can be measured by DXA, which is explained in Appendix E. DXA gives more 
insight in the total amount of lean body mass and fat mass of the body. It is well known that 
obesity is an important risk factor for the development of cardiovascular disease and type 2 
diabetes (35). In children born SGA with spontaneous catch-up in weight, early development of 
adiposity has been reported (36). However, short children born SGA have a different phenotype. 
They have a typical lean appearance, with a low body mass index SDS and a low sum of skinfolds 
SDS (37). Analysing DXA results showed that body fat percentage in short SGA children is 
significantly reduced compared with reference values (38). 
Glucose homeostasis 
Reduced insulin sensitivity also plays an important role in the pathogenesis of cardiovascular 
disease and usually precedes the first symptoms of disease by many years (28,29). To maintain 
a healthy glucose homeostasis, insulin sensitivity and insulin secretion should be balanced. 
A decline in insulin sensitivity is normally compensated by an increase in insulin secretion to 
maintain glucose tolerance. When insulin secretion does not change appropriately, impaired 
glucose tolerance and eventually type 2 diabetes will develop (39). An accurate way to measure 
insulin sensitivity is by means of a Frequently Sampled Intravenous Glucose Tolerance test (FSIGT), 
which is explained in Appendix E (40,41). In a group of prepubertal short SGA children (mean age 
8 years), 8% had an impaired oral glucose tolerance test (42). Further studies indicated that 
short SGA children were more insulin resistant than children with short stature who were born 
appropriate for gestational age, and they had a compensatory higher insulin secretion (43-45). 
Blood pressure and lipid metabolism
Increased blood pressure is an important determinant of cardiovascular disease (46). Next to 
increased diastolic and systolic blood pressure, an increased pulse pressure (the difference 
between systolic blood pressure and diastolic blood pressure), and blood pressure variability in 
time have also been associated with cardiovascular disease (47-49). 
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Raised serum levels of total cholesterol, low-density lipoprotein, and apolipoprotein B together 
with reduced levels of high-density lipoprotein and apolipoprotein A-I also increase the risk for 
CVD (50-52). Short SGA children had a higher systolic blood pressure than references (37,44). Also, 
SGA children reported to have more hypercholesterolemia (53) and more free fatty acid levels 
above the normal range (44) when compared with children born appropriate for gestational age. 
Intima Media Thickness and Pulse Wave Velocity
Atherosclerosis is an important contributor to cardiovascular disease. The presence of 
atherosclerotic changes in the carotid arteries can be determined by investigating the intima 
media thickness (IMT, Appendix E) in the vessel wall of the carotid arteries by non-invasive 
ultrasound measurements (54). A greater thickness is associated with the development of 
atherosclerotic plaques and is positively correlated with cardiovascular events (55,56). Because 
development of atherosclerosis already starts in childhood, determining carotid IMT in early 
adulthood might give more insight in the risk of cardiovascular events in later life. 
 Arterial stiffness is another important determinant of cardiovascular disease, which can be 
quantified by assessing Pulse Wave Velocity (PWV) (57,58). A higher PWV indicates more arterial 
stiffness. 
3 Growth Hormone (GH) treatment in children born SGA
3.1 Effects on linear growth
In 1991, the first Dutch multi-centre randomized double-blind dose-response GH trial was started 
to investigate the efficacy of GH treatment on growth in short SGA children (15,59). Adult height 
data demonstrated that 85% of these children reached a height above -2 SDS and 98% reached 
a height within the target height range (59). In 1996, the second Dutch GH trail was started with 
a randomized control group in which the children were not treated with GH. After three years, 
GH treatment with a dose of 1 mg/m2/day resulted in a normalization of height SDS, whereas 
children in the control group remained short (60). In addition to the Dutch GH trials, several 
other studies have demonstrated that GH treatment effectively induces catch-up growth in short 
SGA children (61-64).
 GH-induced growth response is, however, highly variable (59). For that reason, several 
studies have been conducted to search for clinical predictors of the growth response to GH 
treatment. Patient characteristics found to be related to short-term response were: chronological 
age, bone age, height at start of GH treatment, IGFBP-3 levels and GH dose, explaining 
approximately 40% of the variability in growth response (65). It has also been suggested that pre-
treatment insulin sensitivity significantly influence short-term growth response to GH treatment 
(66), suggesting that short SGA children who are more insulin resistant at baseline have a higher 
risk of glucose intolerance and a lower growth response, which could be considered a warning 
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against treatment (67). Since GH treatment is increasingly applied as a growth-promoting therapy 
in short SGA children, it is important to accurately investigate the relationship between insulin 
levels, insulin sensitivity and GH-induced growth response. 
3.2 Effects on the GH-IGF-IGFBP axis
Previous reports showed that GH treatment of short SGA children leads to increases in serum 
IGF-I and IGFBP-3 levels, which are positively related to the GH dose (8,15,66). After one year of 
GH treatment with a dose of 1 mg/m2/day, a rise of 90% in IGF-I levels was reported, and after 
two years a rise of 123% (8). Another study reported a rise in IGF-I levels up to 1.2 SDS and a rise 
of IGFBP-3 levels up to 0.2 SDS during one years of GH treatment with a dose of 1 mg/m2/day 
(15). Treatment with 2 mg/m2/day resulted in mean IGF-I and IGFBP-3 levels of 1.9 SDS and 0.5 
SDS, respectively (15). After three years of GH treatment, IGF-I and IGFBP-3 levels were similar in 
both GH dose groups (15). At discontinuation of GH treatment after attainment of adult height, 
mean IGF-I SDS was 1.0 in children treated with 1 mg/m2/day and 1.3 in children treated with 2 
mg/m2/day, both significantly higher than the population mean (59). Mean IGFBP-3 levels were 
-0.8 SDS in children treated with 1 mg/m2/day, which is significantly lower than the population 
mean, and -0.06 SDS in children treated with 2 mg/m2/day (59). At 6.5 years after discontinuation 
of GH treatment, IGF-I (-0.4 SDS) and IGFBP-3 (-1.6 SDS) levels had decreased and were similar 
to levels in untreated SGA subjects, indicating that the GH-induced rise in IGF-I and IGFBP-3 was 
completely reversible after discontinuation of treatment (41). 
 During overnight GH profiles in short prepubertal SGA children, mean and maximum GH 
levels were 34.8 and 104 mU/l when treated with 1 mg/m2/day, and 64.4 and 161 mU/l when 
treated with 2 mg/m2/day (68). Because treatment with a GH dose of 1 mg/m2/day is as effective 
as treatment with 2 mg/m2/day with regard to reaching adult height (59) and the long-term risks 
of high GH levels in short SGA children are unknown, most short SGA children are nowadays 
treated with 1 mg/m2/day. 
3.3 Effects on body composition
GH has well-documented anabolic effects on muscle mass and lipolytic effects on adipose tissue 
(69,70). GH deficiency has been associated with increased fat mass and truncal obesity (71), 
whereas GH excess, as in acromegaly, has been related to reduced fat mass and increased lean 
body mass (72). 
 Few studies investigated the effect of GH treatment on body composition in SGA children. 
Leger et al. measured body composition of the thighs during GH treatment by magnetic resonance 
imaging and reported an increase in muscle tissue and a decline in adipose tissue (73). Total body 
fat mass and muscle mass were not measured in this study and only the first three years of 
GH treatment were analysed. Willemsen et al. investigated the effect of GH treatment on body 
composition during six years of GH treatment. They found a significant decline in fat mass SDS 
and no change in lean body mass SDS (74). 
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Discontinuation of GH treatment was associated with significant changes in body composition six 
months after stop of treatment. Percentage body fat and fat mass SDS increased, whereas lean 
body mass SDS decreased (74). Fat distribution had not changed six months after discontinuation 
of GH treatment. All values remained within the normal range and therefore the clinical relevance 
of the observed changes is unclear (74). It remained to be elucidated how body composition 
changes many years after discontinuation of GH treatment. 
3.4 Effects on insulin sensitivity and cardiovascular risk factors
GH has well-documented insulin-antagonistic effects and its use has been associated with a 
reduction in insulin sensitivity and an increase in insulin levels (75-77). Therefore, concerns were 
expressed regarding the long-term effects of GH treatment on risk factors for type 2 diabetes and 
associated comorbidities, especially in possibly predisposed subjects, such as children born SGA. 
Previous research had shown that short SGA children had a reduced insulin sensitivity before 
receiving GH and that GH treatment resulted in a further decline in insulin sensitivity and a 
compensatory increase in insulin secretion (43). 
 Previous studies reported conflicting results regarding the change in insulin sensitivity after 
GH was discontinued. De Zegher et al. observed a decrease in insulin sensitivity in eight short 
SGA children during high dose GH treatment, which was reversible after stop of treatment (66). 
Cutfield et al. measured insulin sensitivity in five short SGA children and reported that insulin 
sensitivity did not recover after discontinuation of GH treatment (43). Both studies investigated 
insulin sensitivity after stop of GH treatment, but still before adult height had been reached. 
Furthermore, it is questionable if the number of subjects was sufficient to draw firm conclusions. 
Willemsen et al. showed that GH-induced lower insulin sensitivity in SGA adolescents increased 
after stop of long-term GH treatment and became similar to that of AGA controls, six months 
after stop of treatment (74). 
 With respect to the other cardiovascular risk factors, GH treatment has been associated 
with a reduction in systolic blood pressure as well as a reduction in cholesterol levels which 
remained so until 6.5 years after discontinuation (41,78). In the same study, at an age of 22 
years, insulin sensitivity and secretion, body mass index and waist circumference in previously 
GH-treated SGA subjects were comparable with those of untreated SGA subjects. 
 Reassuringly, the follow-up studies that have been performed in previously GH-treated 
SGA subjects by our research group do not indicate that GH treatment increased the risk for 
type 2 diabetes and cardiovascular disease. However, long-term surveillance of insulin sensitivity 
and other cardiovascular parameters in previously GH-treated SGA subjects remains important 
to exclude any negative effects of GH. This need for long-term follow-up was also emphasized 
during the SGA consensus meeting in 2007 (1). 
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3.5 Safety aspects of GH treatment
The National Cooperative Growth Study (NGCS) monitored the safety of GH treatment from 
1984 until 1995 in children with various diseases. Reported adverse events included idiopathic 
intracranial hypertension, oedema and lymphedema, carpal tunnel syndrome, slipped capital 
femoral epiphysis, diabetes mellitus and glucose intolerance (79). However, the authors 
concluded that major adverse events in relation to GH treatment were rare and their frequency 
may be affected by pre-existing medical conditions. 
 In SGA children, several studies have shown that GH treatment was well tolerated and that 
side effects were uncommon (37,42,78). Nevertheless, all SGA children receiving GH treatment 
should be monitored regularly for changes in glucose metabolism, lipid profile, blood pressure 
and serum IGF-I levels to exclude any possible adverse effect of GH (1). 
 
PART 2 PREMATURITY
4.1 Preterm birth 
Preterm birth is defined as birth before 37 complete weeks of gestational age. The cause of 
preterm birth is in many situations elusive and unknown; many factors appear to be associated 
with preterm birth, making the reduction of preterm birth a challenging proposition. Table 3 
shows some of the identifiable causes of preterm birth. 
 Nowadays, 5-13% of all newborns in developed countries are born preterm (80). Because 
of advances in neonatal care, survival of preterm infants has significantly improved and an 
increasing number of these children reach adulthood. 
4.2 Preterm birth and risk for cardiovascular disease
Small size at birth may be due to preterm birth, poor fetal growth, or a combination of both. 
Most studies on the effect of small size at birth and risk for adult diseases, focused on subjects 
with a low birth weight and did not have information on gestational age, did not correct for it, 
or only included subjects born term. It is, therefore, difficult to determine whether the effect of 
small size at birth on cardiovascular risk factors in later life is due to a small size for gestational 
age (SGA) or to prematurity.
 Preterm infants are frequently exposed to early postnatal growth restriction, glucocorticoid 
treatment, and stressful events. This may be important in the development of later organ 
dysfunction and adverse vascular outcome. To date, most long-term follow-up studies have 
focused on neurodevelopmental and respiratory complications of preterm infants, with little 
attention for the cardiovascular outcome. 
 Preterm birth has been associated with an increased risk of developing cardiovascular 
disease (81,82) and with increased cardiovascular mortality (83). We, therefore, investigated the 
relative contribution of prematurity and SGA on several parameters for cardiovascular diseases 
in young adulthood. 
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Table 3. Identifiable causes of preterm birth
Fetal 
Fetal distress
Multiple gestation
Erythroblastosis
Nonimmune hydrops
Placental
Placental dysfunction
Placenta previa
Abruptio placentae
Uterine
Bicornuate uterus
Incompetent cervix Premature dilatation
Maternal
Pre-eclampsia
Chronic medical illness Cyanotic heart disease
Renal disease
Infection Listeria monocytogenes
Group B streptococcus
Urinary tract infection
Bacterial vaginosis
Chorioamnionitis
Drug abuse Cocaine
Other
Premature rupture of membranes
Polyhydramnios
Iatrogenic
Trauma
Adapted from Nelson Textbook of Pediatrics, 18th edition.
 
4.3 Preterm birth and bone mineral density 
Decreased mineralization of osteoid tissue during the early postnatal period is a known 
complication of very low birth weight and/or prematurely born infants (84-86). It comprises 
a variety of disturbances ranging from mild undermineralization to frank radiological rickets 
with fracture (87). Preterm infants are at an increased risk of low bone mineral density as bone 
mineralization, along with calcium and phosphorus accretion, mainly occurs during the third 
trimester of pregnancy (88). 
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Osteoporosis is an important and increasing cause of morbidity and mortality in developed 
countries. It is characterized by low bone mass, deterioration of bone tissue and disruption of 
bone architecture, compromised bone strength and an increase in the risk of fracture (89). Since 
early prevention of osteoporosis is likely to be more successful than treatment of an already 
established disorder, it is essential to identify potential risk factors, like preterm birth. 
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5 AIMS OF THE STUDY
PART 1 SMALL FOR GESTATIONAL AGE
Factors associated with GH-induced growth response 
GH treatment induces catch-up growth and increases adult height in short SGA children. GH 
response is, however, highly variable. It has been suggested that pre-treatment fasting insulin 
sensitivity significantly influences short-term growth response to GH treatment. We, therefore, 
investigated the relationship between fasting insulin levels, insulin sensitivity and β-cell function, 
measured by a frequently sampled intravenous glucose tolerance test with Tolbutamide, and 
parameters of the GH-IGF-IGFPB axis, also including overnight GH profiles and free IGF-I, and the 
GH-induced growth response in short SGA children. 
Health profile after discontinuation of GH treatment
Despite the fact that GH has been used for more than 25 years, there are only limited data 
available on the longitudinal effects after discontinuation of this treatment. We investigated 
longitudinal changes in several determinants for cardiovascular disease and type 2 diabetes until 
almost 7 years after discontinuation of GH treatment. Body composition and fat distribution were 
determined by DXA. Secondly, we evaluated insulin sensitivity and β-cell function, measured by a 
frequently sampled intravenous glucose tolerance test with Tolbutamide. Finally, lipid levels and 
blood pressure were measured. 
PART 2 PREMATURITY
Since both SGA and preterm birth have been associated with an increased risk of developing 
adult diseases, we investigated the relative contribution of prematurity and SGA on several 
parameters for cardiovascular diseases and bone mineral density in young adulthood. 
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6 OUTLINE OF THIS THESIS
Chapter 1 gives an introduction in the topics described in this thesis.
Chapter 2 reports on the effect of insulin sensitivity and the GH-IGF-IGFBP axis on the GH induced 
growth response in short children born SGA, before and during GH treatment. 
Chapter 3 describes body composition and fat distribution in previously GH-treated young SGA 
adults at 6.8 years after discontinuation of GH treatment. 
Chapter 4 reports on alterations in body composition, lipid levels and blood pressure until two 
years after discontinuation of GH treatment in subjects born SGA. 
Chapter 5 reports on longitudinal changes in insulin sensitivity, insulin secretion and body 
composition in previously GH-treated young adults born SGA, until five years after discontinuation 
of GH treatment. 
Chapter 6 describes the effect of preterm birth on body composition, especially fat mass, and 
lipid profile. 
Chapter 7 describes the effect of preterm birth on several determinants of cardiovascular disease 
in early adulthood, including effects of birth size and growth patterns.
Chapter 8 describes the effect of preterm birth on bone mineral density in young adults.
Chapter 9 discusses our findings in relation to current literature and comments on the clinical 
implications and conclusions of our study results.
Chapter 10 summarizes our findings in English.
Chapter 11 summarizes our findings in Dutch.
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APPENDIX A
IUGR-1 study
Inclusion criteria
1. Birth length and/or birth weight SDS below -1.88 (comparable to 3rd percentile) for 
gestational age (90); 
2. An uncomplicated neonatal period, without signs of severe asphyxia (defined as Apgar 
score below 3 after 5 minutes), sepsis or long-term complications of respiratory ventilation 
such as bronchopulmonary dysplasia;
3. Chronological age between 3.00 and 10.99 for boys and between 3.00 and 8.99 for girls at 
start of the study; 
4. Height SDS for age below -1.88 according to Dutch reference values (91);
5. Height velocity SDS for age below zero to exclude children with spontaneous catch-up 
growth (91);
6. Prepubertal, defined as Tanner stage 1 or testicular volume smaller than 4 ml (92);
7. Normal liver, kidney and thyroid functions.
Exclusion criteria
1. Any endocrine or metabolic disorder such as diabetes mellitus, diabetes insipidus, 
hypothyroidism, or inborn errors of metabolism, except for growth hormone deficiency; 
2. Disorders of major organs; 
3. Chromosomal abnormalities or signs of a syndrome, except Silver Russell Syndrome;
4. Chondrodysplasia; 
5. Hydrocephalus; 
6. Active malignancy or increased risk of leukaemia; 
7. Serious suspicion of psychosocial dwarfism (emotional deprivation);
8. Previous anabolic sex steroid of GH treatment. 
Design 
The IUGR-1 study started in 1991. The study design was a multi-centre, randomized, double-blind, 
dose-response GH trail. After stratification for age and for spontaneous GH secretion, all children 
were randomly and blindly assigned to either 1 mg GH/m2/day (group A) or 2 mg GH/m2/day 
(group B). Biosynthetic GH (r-hGH Norditropin®, Novo Nordisk A/S, Bagsværd, Denmark) was 
given subcutaneously once daily at bedtime. Three-monthly, the GH dose was adjusted to the 
calculated body surface area. 
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APPENDIX B
IUGR-2 study
Inclusion criteria
1. Birth length and/or birth weight SDS below -1.88 (comparable to 3rd percentile) for 
gestational age (90);
2. An uncomplicated neonatal period, without signs of severe asphyxia (defined as Apgar 
score below 3 after 5 minutes), sepsis or long-term complications of respiratory ventilation 
such as bronchopulmonary dysplasia;
3. Chronological age between 3.00 and 7.99 years at start of the study;
4. Height SDS for age below -1.88 according to Dutch reference values (91);
5. Height velocity SDS for age below zero to exclude children with spontaneous catch-up 
growth (91);
6. Prepubertal, defined as Tanner stage 1 or testicular volume smaller than 4 ml (92);
7. Normal liver, kidney and thyroid functions.
Exclusion criteria
1. Any endocrine or metabolic disorder such as diabetes mellitus, diabetes insipidus, 
hypothyroidism, or inborn errors of metabolism, except for growth hormone deficiency; 
2. Disorders of major organs;
3. Chromosomal abnormalities or signs of a syndrome, except Silver Russell Syndrome; 
4. Chondrodysplasia; 
5. Hydrocephalus; 
6. Active malignancy or increased risk of leukaemia; 
7. Serious suspicion of psychosocial dwarfism (emotional deprivation);
8. Previous anabolic sex steroid of GH treatment. 
Design 
The IUGR-2 study started in 1996. The study was an open-labelled, multi-centre study with a 
randomized control group, which included 174 short children born SGA. Before entering the 
study, the GH status was evaluated in all children using GH stimulation tests (arginine and/or 
clonidine). Children with GH deficiency, which was defined as a GH peak <10 mcg/l during two 
stimulation tests, were not randomized but started with treatment at a dose of 1 mg GH/m2/day 
(GHD-group). The non-growth hormone deficient children were stratified according to age (3.00-
5.50 versus 5.50-7.99 years) and height of the parents (height of both parents above -1.88 SDS 
versus height of at least one parent below -1.88 SDS). After stratification, children were randomly 
assigned to either the GH-group (2/3 of the children) or the control group (1/3 of the children). 
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The GH-group started immediately with treatment at a dose of 1 mg GH/m2/day. The control 
group remained untreated for three years and subsequently received the same GH treatment as 
the GH-group. Biosynthetic GH (r-hGH Norditropin®, Novo Nordisk A/S, Bagsværd, Denmark) was 
given subcutaneously once daily at bedtime. Three-monthly, the GH dose was adjusted to the 
calculated body surface area. 
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APPENDIX C
IUGR-3 study
Inclusion criteria
1. Birth length and/or birth weight SDS below -2.00 for gestational age (90);
2. An uncomplicated neonatal period, without signs of severe asphyxia (defined as Apgar 
score below 3 after 5 minutes), sepsis or long-term complications of respiratory ventilation 
such as bronchopulmonary dysplasia;
3. Chronological age between 3.00 and 7.99 years at start of the study;
4. Height SDS for age below -2.50 according to Dutch reference values (91);
5. Height velocity SDS for age below zero to exclude children with spontaneous catch-up 
growth (91);
6. Prepubertal, defined as Tanner stage 1 or testicular volume smaller than 4 ml (92);
7. Normal liver, kidney and thyroid functions.
Exclusion criteria
1. Any endocrine or metabolic disorder such as diabetes mellitus, diabetes insipidus, 
hypothyroidism, or inborn errors of metabolism, except for growth hormone deficiency; 
2. Disorders of major organs; 
3. Chromosomal abnormalities or signs of a syndrome, except Silver Russell Syndrome; 
4. Chondrodysplasia; 
5. Hydrocephalus; 
6. Active malignancy or increased risk of leukaemia; 
7. Serious suspicion of psychosocial dwarfism (emotional deprivation); 
8. Previous anabolic sex steroid of GH treatment. 
Design 
The IUGR-3 study started in 2002. The study design was an open-labeled, randomized, multi-
centre study. After stratification for gender, GH-status (maximum serum GH between 20-30 mU/l 
versus serum GH >30 mU/l during a GH stimulation test) and BMI (<-1 SDS versus >-1 SDS), 
children were randomized into 2 different groups. During 6 months, children in group A received 
1 mg GH/m2/day and those in group B received 2 mg GH/m2/day. Subsequently, all children 
received the same dose of 1 mg GH/m2/day. Biosynthetic GH (r-hGH Norditropin® Novo Nordisk 
A/S, Denmark) was given subcutaneously once daily at bedtime. Three-monthly, the GH dose 
was adjusted to the calculated body surface area. 
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APPENDIX D
The PROGRAM and PREMS study cohort
The PROgramming factors for Growth And Metabolism (PROGRAM) study consists of 323 healthy 
young adults born term, whereas the Prematurity and Small for Gestational Age (PREMS) study 
cohorts consists of 169 healthy young adults born preterm (gestational age <36 weeks). In these 
participants, several parameters for cardiovascular disease and type 2 diabetes were determined.
Inclusion criteria
1. Chronological age at inclusion: 18.00-23.99 years; 
2. Neonatal period without signs of severe asphyxia (defined as an Apgar score <3 after 
5  minutes), no serious diseases such as long-term artificial ventilation and oxygen 
supply,  bronchopulmonary dysplasia or other chronic lung disease;
3. Well documented growth data;
4. Caucasian; 
5. Born singleton; 
6. Signed informed consent; 
7. PROGRAM study: gestational age of 36 weeks or more;
8. PREMS study: gestational age of less than 36 weeks. 
Exclusion criteria
1. Chromosomal disorders, known syndromes and serious dysmorphic symptoms suggestive 
for a yet unknown syndrome, except Silver-Russell Syndrome; 
2. Any disease, endocrine or metabolic disorder that could interfere with growth during 
childhood (such as diabetes, growth hormone deficiency, malignancies, severe chronic 
disease);
3. Treatment that could have interfered with growth (such as radiotherapy or growth hormone 
treatment); 
4. Serious suspicion of psychosocial dwarfism (emotional deprivation) during childhood. 
Study design
To investigate the influence of different growth patterns during childhood on determinants 
of adult disease, we oversampled subjects with extreme variants of normal growth, such as 
subjects born small for gestational age (SGA) (with and without catch-up growth) and subjects 
with unknown growth retardation during childhood (idiopathic short stature (ISS)). This design 
created greater contrast in the study population, which contributed to more statistical power. 
 For subgroup analyses, the total study population was divided into four clinically relevant 
subgroups based on birth length and adult height. Two subgroups consisted of small for 
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gestational age (SGA) born adults, one without catch-up growth (SGA-S) and one with catch-
up growth (SGA-CU). The last two subgroups consisted of young adults born appropriate for 
gestational age: one with short adult stature without known reason (idiopathic short stature) 
and one with normal adult height (controls).
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APPENDIX E
Dual Energy X-ray Absorptiometry (DXA)
DXA is a machine used to measure bone mineral density and body composition (fat mass and 
lean body mass). The person being assessed lies still for about 15 minutes while a scanner slides 
over the participant. DXA uses X-rays to assess these measures, but the radiation dose is about 
1/10th of a chest X-ray. 
Frequently Sampled Intravenous Glucose Tolerance Test (FSIGT)
Several values regarding glucose homeostasis can be measured by FSIGT: 1) insulin sensitivity 
(Si), which quantifies the capacity of insulin to promote glucose disposal; 2) glucose effectiveness 
(Sg), which reflects the capacity of glucose to mediate its own disposal; 3) acute insulin response 
to glucose (AIRg), which is an estimate of insulin secretory capacity; and 4) the disposition index 
(DI), the product of SI and AIRg indicating the degree of glucose homeostasis. These indicators of 
glucose regulation were determined by the Bergman’s minimal model (MINMOD 6.01 copyright 
RN Bergman) calculating paired glucose and insulin data obtained by frequent measurements 
during an FSIGT with Tolbutamide (93-96). 
 When SI varies in healthy subjects, these changes are compensated proportionally by 
insulin secretion; reduced insulin sensitivity leads to increased insulin secretion by the beta-cells 
(Figure 3) (97). If insulin secretion does not change appropriately, impaired glucose tolerance 
and eventually  type 2 diabetes will develop (39).
Figure 3. Hyperbolic association between insulin secretion and insulin sensitivity.
Adapted from Kahn et al. (74). IGT: impaired glucose tolerance, T2DM: type 2 diabetes mellitus
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Carotid Intima Media Thickness 
Intima media thickness (IMT) is the thickness of the two inner layers of an arterial wall. The 
thickness of the intima media of the carotid artery is related to atherosclerosis in later life 
(54,98). Carotid IMT was measured in supine position by recording of ultrasonographic images 
of both left and right carotid artery, using a 7.5 MHz linear array transducer (ALT Ultramark IV, 
Advanced Tech. Laboratories, Bethel Washington, USA). On the R wave of the electrocardiogram, 
three longitudinal images of the near and far wall of the common carotid artery were frozen 
and stored on videotape. These frozen images were digitalized and displayed on the screen of 
a computer using a frame grabber (VP 1400-KIT-512-E-AT, Imaging Technology). The common 
carotid IMT was determined as the mean of the mean near and far wall measurements of both 
the left and right side common carotid artery (98).
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Abstract
Context: GH treatment of short children born small for gestational age (SGA) results in a decline 
in fat mass (FM) and an increase in lean body mass (LBM). It is, however, unknown whether these 
changes persist into adulthood.
Objective: Our objective was to assess the long-term impact of GH treatment during childhood 
on body composition and fat distribution.
Patients and Design: A total of 377 young adults participated in this cross-sectional study: 59 
previously GH-treated young SGA adults compared to 52 untreated SGA adults with short stature 
(SGA-S), 161 SGA adults with spontaneous catch-up growth (SGA-CU), and 105 healthy normal- 
statured controls born appropriate for gestational age (AGA).
Outcome Measures: Body composition and fat distribution were determined by dual-energy 
x-ray absorptiometry.
Results: Mean (SD) duration of GH treatment was 7.7 (2.4) yr and period after discontinuation 6.8 
(1.8) yr. FM, fat distribution, and LBM of GH-treated SGA adults were not significantly different 
from that of untreated SGA-S adults. GH-treated SGA adults also had a similar FM and fat distri- 
bution as SGA-CU adults but a lower LBM. All SGA subgroups had a lower LBM and tended to 
have a higher FM than healthy AGA controls.
Conclusion: Body composition and fat distribution of previously GH-treated SGA adults were 
similar to those of untreated SGA-S adults. GH-induced catch-up growth has no unfavorable 
effect on FM and fat distribution compared with spontaneous catch-up growth. However, our 
study shows that SGA adults in general may have a different body composition than healthy AGA 
controls. 
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Introduction
Studies on postnatal growth in infants born small for gestational age (SGA) or with intrauterine 
growth retardation have shown that, although these infants generally show spontaneous catch-
up growth in height, approximately 10% of them remain short, with a height below -2 SD score 
(SDS) (1,2). SGA children who remain short tend to have a typical lean appearance with a low 
body mass index (BMI) (3). We previously showed that this leanness is characterized by a marked 
reduction of lean body mass (LBM) and to a lesser extent a lower total fat mass (FM) (4). GH 
treatment of these children resulted in a decline in FM and an increase in LBM, which is con- 
sistent with the lipolytic and anabolic properties of GH (4,5). De Kort et al. (6) showed that this 
decrease in FM is mainly located in the limbs of GH-treated SGA children, whereas the amount 
of trunk fat remains stable.
 Obesity is a global and increasing problem with major public-health consequences (7). It is 
a risk factor for several adult diseases, including type 2 diabetes, the metabolic syndrome, and 
cardiovascular diseases. Previous studies showed that growth during infancy is an important 
determinant of body composition in young adulthood. Faster weight gain in infancy is associated 
with a greater risk of obesity later in life, whereas birth size is less important (8-10). Infants born 
SGA, however, are more likely to show catch-up growth in weight than infants born appropriate 
for gestational age (AGA) and could therefore be at greater risk of developing obesity later in 
life. Because GH treatment induces catch-up growth, concern has been expressed regarding the 
long-term effects of GH treatment on body composition (11).
 The primary aim of this study was to investigate the impact of GH treatment during 
childhood on body composition and fat distribution in young adulthood in subjects born SGA, 
many years after discontinuation of GH. To answer this question, we compared previously GH- 
treated SGA adults with untreated SGA adults with short stature (SGA-S). We hypothesized that 
the body composition of GH-treated adults returns to levels of those who were never treated, 
especially because BMI SDS and waist circumference are comparable for GH-treated and un- 
treated SGA adults with short stature (12). Our second aim was to evaluate whether GH-induced 
catch-up growth had a different effect on young adult body composition than spontaneous 
catch-up growth, and whether the various SGA groups had a different body composition and fat 
distribution than healthy AGA controls.
Subjects and Methods
Subjects
The total study group comprised 377 young adults, divided into 59 previously GH-treated adults 
born SGA who had previously been participating in a multicenter, double-blind, randomized, 
dose-response GH trial (13,14); 52 untreated SGA-S (adult height <-2 SDS); 161 SGA adults with 
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spontaneous catch-up growth (SGA-CU) (adult height >-2 SDS); and 105 healthy, normal-statured 
adult controls who were born AGA (defined as birth length and adult height >-2 SDS). The SGA-S, 
SGA-CU, and AGA adults were part of a cohort of young adults participating in a national study 
evaluating risk factors for diabetes mellitus type 2 and cardiovascular disease, the PROGRAM 
study (8).
 The dose-response GH trial started in 1991 and evaluated the effect of two doses of GH, 1 
and 2 mg/m2/day, on long-term growth and adult height. The inclusion criteria for the GH trial 
have been described (13). GH treatment was discontinued when height velocity had dropped 
below 0.5 cm over the preceding 6 months and when bone age was at least 15 yr for girls and at 
least 16.5 yr for boys. Patients were included in the present study when they had been treated 
with GH for more than 4 yr and had discontinued GH treatment for more than 4 yr. Thirty-one 
of the original 90 participants were not included for the following reasons: one subject had 
discontinued GH treatment less than 4 yr earlier; five children dropped out during the original 
GH trial due to lack of motivation (n=3), precocious puberty (n=1), or GH insensitivity (n=1); one 
subject was not included due to psychosocial problems; four subjects were lost to follow-up; two 
subjects emigrated; one subject had died due to a road acciden; five persons did not respond 
to the invitation letter, and 12 subjects did not want to participate due to lack of interest. The 
clinical characteristics of the 59 GH-treated SGA subjects who were included were comparable 
with those of the 31 subjects who were not included, except for age at discontinuation of GH 
treatment (15.7 vs. 14.8 yr, respectively; P=0.001).
 The studies were approved by the Medical Research Ethics Committees of the participating 
centers. Written informed consent was obtained from all participants or their parents.
Measurements
Standing height was measured in the upright position to the nearest 0.1 cm using a Harpenden 
stadiometer (Holtain, Ltd., Crymmyth, UK). Sitting height (SH) was measured to the nearest 0.1 
cm using a Harpenden SH table. SH to height ratio was then calculated and expressed as SDS 
adjusted for age and gender (15). Weight was measured to the nearest 0.1 kg on a digital scale 
(Servo Balance KA-20-150S, Servo Berkel Prior, Katwijk, The Netherlands). BMI was calculated 
by dividing weight in kilograms by the square of height in meters and rounded to the nearest 
tenth. Waist circumference was measured at the level of the umbilicus using a nonextendable 
measuring tape. All anthropometric measurements were performed at least twice according 
to standardized methods, after which the mean was calculated. Height, BMI, and waist 
circumference were expressed as SDS adjusted for age and gender according to Dutch reference 
data for children (16-18).
 In all participants, total FM, trunk FM, limb FM, and LBM were measured on one dual-
energy x-ray absorptiometry (DXA) machine (Lunar Prodigy; GE Healthcare, Chalfont St. Giles, 
UK). Quality assurance was performed daily. For this type of DXA, the intraassay coefficient of 
variation has been reported to be 0.41-0.88% for fat tissue and 1.57-4.49% for LBM (19).
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Statistics
Data are expressed as mean ±SDS. Statistical analyses within the GH-treated SGA group were 
performed for the GH dosage groups separately (1 vs. 2 mg/m2/day) and for the groups together. 
Because the outcome variables were the same in both GH dosage groups, data are shown for the 
groups together.
 Differences in clinical characteristics between the GH-treated SGA adults, and SGA-S, 
SGA-CU, and AGA adults were evaluated using independent-samples t tests. Differences in 
body composition and fat distribution between the GH-treated SGA adults, and the other three 
subgroups were determined using analyses of covariance, with correction for age, gender, 
gestational age, and adult height SDS. In the analyses, GH-treated SGA adults were defined as 1 
and the other groups as 0.
 The effect of the duration of GH treatment on total FM, trunk FM, limb FM, and LBM was 
analyzed using multiple regression analyses, corrected for possible confounders (age, gender, 
gestational age, height SDS, weight SDS, birth length SDS, and birth weight SDS). The interaction 
term birth length SDS * adult height SDS was added to the multiple regression model to ensure 
that the effect of these variables was modeled correctly (20). Oral contraceptive use and serum 
IGF-I levels at time of the present follow-up study (levels <-2 SDS used as proxy for GH deficiency) 
were added to the original models, but these did not change the results. Due to the lack of a 
significant contribution, these independent variables were deleted from the final models.
 In addition, the means of the different parameters of body composition adjusted for age, 
gender, gestational age, and height SDS were calculated using univariate ANOVA, resulting in 
estimated marginal means (EMM). Based on the EMM, the differences in body composition 
between the three SGA subgroups and the healthy AGA controls were determined via pairwise 
comparisons.
 Before the study, a power analysis with a significance level (α) of 0.05 and a chosen power 
of 80% estimated that there should be at least 22 subjects in each group to allow detection of 
a relevant difference of 10% in LBM. Results were regarded as statistically significant at P<0.05. 
Statistics were performed using the computer Statistical Package for Social Science (SPSS version 
17.0; SPSS Inc., Chicago, IL).
Results
Clinical characteristics
The clinical characteristics of the four subgroups are shown in Table 1. GH-treated SGA adults 
were 22.5 (2.0) yr old. At the start of GH treatment, mean height SDS was -3.0, and mean age 
at start of GH treatment was 8.0 yr. The mean (SDS) duration of GH treatment was 7.7 (2.4) yr 
and the period after discontinuation of GH 6.8 (1.8) yr. GH-treated SGA adults had a significantly 
smaller size at birth (birth weight and/or birth length) than the SGA-S, SGA-CU, and AGA adults.
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Table 1. Unadjusted clinical characteristics
GH-treated  
SGA  
(n=59)
Untreated 
SGA-S  
(n=52)
P  
valuea
SGA-CU 
(n=161)
P  
valueb
AGA  
controls 
(n=105)
P  
valuec
Gender (male/female) 34/25 18/34 72/89 34/71
Gestational age 36.6 (3.8) 37.9 (3.0) 0.051 36.6 (3.6) 0.892 39.4 (1.5) <0.001
Birth weight SDS -2.7 (1.0) -2.3 (0.8) 0.013 -2.3 (0.7) 0.011 -0.1 (1.1) <0.001
Birth length SDS -3.5 (1.3) -3.0 (0.9) 0.031 -2.7 (1.0) <0.001 -0.3 (0.9) <0.001
Age 22.5 (2.0) 20.9 (1.7) <0.001 20.9 (1.7) <0.001 20.9 (1.7) <0.001
Height SDS -1.6 (1.1) -2.5 (0.6) <0.001 -0.4 (0.9) <0.001 0.1 (1.1) <0.001
BMI SDS 0.3 (1.2) 0.3 (1.6) 0.799 0.3 (1.4) 0.857 0.1 (0.9) 0.191
Waist circumference SDS -0.3 (1.3) -0.2 (1.4) 0.923 0.4 (1.2) <0.001 0.2 (1.0) 0.018
Ratio SH/height SDS 1.6 (1.3) 1.6 (1.2) 0.950 0.7 (2.8) 0.028 0.2 (1.7) <0.001
IGF-I SDS -0.4 (1.0) -0.5 (0.9) 0.583 -0.4 (0.9) 0.828 -0.4 (1.0) 0.874
Data are expressed as mean (SDS).
a Differences between GH-treated SGA and untreated SGA-S.
b Differences between GH-treated SGA and SGA-CU.
c Differences between GH-treated SGA and AGA controls.
At time of the present follow-up study, previously GH-treated SGA adults were 1.6 yr older than 
untreated SGA-S adults, SGA-CU adults, and AGA controls. GH-treated SGA adults were taller 
than the untreated SGA-S adults and shorter than the SGA-CU adults and AGA controls. GH-
treated SGA adults had a similar SH to height ratio SDS as SGA-S and SGA-CU adults. This ratio 
was higher in SGA adults, either GH-treated or not, than in AGA controls. At the time of the 
present study, waist circumference SDS of GH-treated adults was similar to that of SGA-S adults 
but differed from those of SGA-CU and AGA adults. BMI SDS and serum IGF-I level SDS of the GH-
treated SGA adults were comparable to those of the other three subgroups.
Body composition
Unadjusted body composition data are shown in Table 2. The differences between the GH-treated 
SGA adults and the other subgroups are given after correction for age, gender, gestational age, 
and adult height SDS.
GH-treated SGA vs. SGA-S
Total FM of GH-treated SGA adults was similar to that of untreated SGA-S adults. Fat distribution 
(trunk FM and limb FM) was also comparable for GH-treated SGA and untreated SGA-S adults. 
Unadjusted LBM seems to be higher in GH-treated SGA than in untreated SGA-S adults. However, 
after necessary adjustments for age, gender, gestational age and height SDS, the adjusted LBM 
of GH-treated SGA adults tended to be lower than untreated SGA adults (GH-treated vs. SGA-S 
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β=-2188; P=0.063). After additional adjustment for birth weight SDS and birth length SDS, 
because GH-treated SGA adults were the smallest at birth, this difference disappeared (P=0.130).
GH-treated SGA vs. SGA-CU
GH-treated SGA adults had a similar total FM and fat distribution as SGA-CU. LBM was lower in 
GH-treated SGA adults than in SGA-CU adults.
SGA subgroups vs. healthy AGA controls
The EMM for all body composition parameters and differences between the SGA subgroups 
and the healthy AGA controls are shown in Figures 1-4. These EMM are adjusted for several 
variables such as adult height SDS and gender. Because the subgroups differ in, for example, 
gender and adult height SDS, it is important and more valuable to show these adjusted values. 
All SGA subjects had a higher adjusted total FM and adjusted limb FM than healthy AGA controls, 
but these differences were signifi- cant only for the SGA-CU adults compared with AGA controls 
(P<0.001). Adjusted trunk FM was also higher in all SGA subgroups but did not reach significance 
in the SGA-S adults (P=0.100), probably due to a lower number of subjects. In addition, all SGA 
subgroups had a lower adjusted LBM than healthy AGA controls.
Figure 1. EMM of total FM of the three SGA 
subgroups compared with AGA controls (with 
95% CI), adjusted for age, gender, gestational 
age and height SDS. *, P<0.001 compared 
with AGA controls.
Figure 2. EMM of trunk FM of the three SGA 
subgroups compared with AGA controls (with 
95% CI), adjusted for age, gender, gestational 
age, and height SDS. *, P<0.001 compared with 
AGA controls; #, P<0.05 compared with AGA 
controls.
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Figure 3. EMM of limb FM of the three SGA 
subgroups compared with AGA controls (with 
95% CI), adjusted for age, gender, gestational 
age, and height SDS. *, P<0.001 compared 
with AGA controls.
Figure 4. EMM of LBM of the three SGA 
subgroups compared with AGA controls (with 
95% CI), adjusted for age, gender, gestational 
age, and height SDS. *, P<0.001 compared with 
AGA controls; #, P<0.05 compared with AGA 
controls.
Duration of GH treatment
Within the GH-treated SGA adults, multiple regression models were used to determine the 
influence of the duration of GH treatment on body composition. The duration of GH treatment 
did not have an effect on total FM (β=484; P=0.199), trunk FM (β=291; P =0.199), limb FM 
(β=183; P=0.239), and LBM (β=-256; P=0.523), after adjustment for possible confounders (age, 
gender, gestational age, birth length SDS, birth weight SDS, adult height SDS, and adult weight 
SDS), many years after discontinuation of GH.
Discussion
This study compared the body composition and fat distribution of previously GH-treated SGA 
adults, at 6.8 yr after discontinuation of GH treatment, with those of untreated SGA-S, SGA-CU, 
and healthy AGA controls.
 FM, fat distribution, and LBM of GH-treated SGA adults were not significantly different 
from those of untreated SGA-S. As indicated by Willemsen et al. (21), significant changes in 
body composition occur in previously GH-treated SGA adults after stopping GH treatment. They 
showed that at 6 months after GH discontinuation (mean age subjects 16 yr), fat percentage and 
FM had increased, whereas LBM had decreased. In a group of 10 SGA subjects who were treated 
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with GH for a period of 3 yr, Leger et al. (5) also showed a tendency to a decreased LBM and 
a significant increase in adipose tissue 3 months after GH discontinuation. These changes are 
opposite to those that occur during GH treatment in SGA children (22), i.e. an increase in LBM 
and a decrease in FM (4,5). In our cohort of young adults many years after discontinuation of GH 
treatment, FM and LBM levels were similar to those of untreated SGA-S. So despite an increase 
in FM and decrease in LBM after discontinuation of GH treatment, previously GH-treated SGA 
adults have a similar body composition as those who remained untreated. Furthermore, duration 
of GH treatment did not have any effect on body composition in young adulthood.
 GH-treated SGA adults had a similar total FM and fat distribution as SGA-CU, which indicates 
that GH-induced catch-up growth has no unfavorable effect on FM compared with spontaneous 
catch-up growth. GH-treated SGA adults had, however, a lower LBM than SGA-CU adults, which 
is in line with the body composition of SGA children with short stature characterized by, among 
other things, a reduced LBM.
 Furthermore, all SGA adults (GH-treated, SGA-S, and SGA-CU) tended to have a higher 
total FM and a higher trunk FM and limb FM than healthy AGA controls and had a lower LBM 
than the control subjects. These observed differences in body composition and fat distribution 
between SGA adults and controls probably indicate that SGA adults in general have a different 
body composition than healthy AGA controls. Using DXA trunk FM as a surrogate for abdominal 
FM and knowing that abdominal obesity is a risk factor for the development of metabolic 
abnormalities (23,24), our study suggests that all SGA-born adults might have a higher risk of 
developing diabetes mellitus type 2 and cardiovascular diseases than normal-statured healthy 
AGA controls.
 The SGA-CU subjects had the highest amount of FM (total, trunk, and limb) of all three 
SGA subgroups and differed most significantly from healthy AGA controls. This is in line with 
previous research by Leunissen et al. (8) and Ibáñez et al. (25,26) who reported that SGA-CU 
gained more body adiposity and abdominal fat than AGA infants. Previous systematic reviews 
have also described a very consistent association between rapid weight gain during infancy and 
subsequent adiposity risk in childhood and later life (27-29).
 To our knowledge, this is the first study investigating the long-term effects of GH on body 
composition many years after discontinuation of treatment in adults born SGA. Because body 
composition is greatly influenced by age, gender, and height (16), differences in body composition 
were evaluated after correction for these variables. Because gestational age was significantly 
different between the four subgroups and previous research suggests that gestational age might 
be of influence on later body composition (30), we also adjusted for this possible confounder in 
our analyses.
 The GH-treated SGA subjects started GH treatment relatively late, around 8 yr of age. Our 
results demonstrate that GH treatment does not have an unfavorable effect on body composition 
in young adulthood, many years after stopping GH. However, the beneficial effects of GH on body 
composition during treatment, i.e. an increase in LBM and a decrease in FM, did not remain 
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either. It has been suggested that the adverse effects of poor intrauterine growth on the adipose 
tissue is most prominent in the first years of life. Ibáñez et al. (31) showed that girls born SGA, 
aged 2-8 yr, tend to follow an altered developmental trajectory that may lead to abnormal fat 
storage in puberty and adulthood. One could speculate that the lack of a positive effect of GH 
treatment on body composition, many years after its discontinuation, might be due to the fact 
that GH treatment was not started in the early years of life. Nowadays, some studies start GH 
treatment in (much) younger SGA children (32-34). It would be interesting to evaluate whether 
these children have a different adipose tissue development, particularly in the long term.
 In conclusion, our study shows that at 6.8 yr after discontinuation of long-term GH 
treatment, body composition of previously GH-treated SGA adults is similar to that of untreated 
SGA-S. These data are reassuring, because they suggest that long-term GH treatment of SGA 
children with short stature does not have an unfavorable effect on body composition in young 
adulthood. Second, our study shows that SGA adults in general may have a different body 
composition from healthy AGA controls. It remains to be elucidated how body composition and 
fat distribution develop when these subjects become older.
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Abstracts
Context: Associations between small size at birth and abnormal cardiovascular parameters 
in later life have been reported. It is, however, unknown whether the effect of a small size at 
birth on cardiovascular risk factors in later life is due to a small size for gestational age or due 
to prematurity. Due to advances in neonatal care, survival of preterm infants has significantly 
improved, and nowadays an increasing number of these children reach adulthood. It is, therefore, 
of increasing importance to assess the long-term effect of prematurity on determinants for 
cardiovascular disease.
Objective: The aim of the study was to assess the long-term effects of gestational age and partic- 
ularly preterm birth on lipid levels and fat mass in early adulthood.
Design and Patients: A cross-sectional study was conducted with 455 healthy subjects, aged 18 
to 24 yr; 167 preterm subjects were compared with 288 full-term subjects.
Outcome Measure: Total fat mass, trunk fat mass, and limb fat mass were determined by 
dual- energy x-ray absorptiometry. Furthermore, fasting lipid levels (total cholesterol, low-
density lipoprotein, triglyceride, apolipoprotein B, lipoprotein a, high-density lipoprotein, and 
apolipoprotein A-I) were measured.
Results: Preterm subjects had a significantly higher percentage of total fat mass, trunk fat mass, 
and limb fat mass than subjects born term. Furthermore, preterm subjects had significantly 
lower serum lipoprotein a levels and higher apolipoprotein A-I levels than term subjects. Multiple 
linear regression analyses to assess the association between gestational age and fat mass and 
lipid levels showed similar results.
Conclusion: In our cohort of 455 young adults, preterm birth was associated with more total fat 
mass, trunk fat, and limb fat mass but a relatively favorable lipid profile. 
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Introduction
Dyslipidemia is one of the major determinants for cardiovascular disease (CVD) and is characterized 
by raised levels of total cholesterol (TC), low-density lipoprotein (LDLc), triglyceride (Tg), 
apolipoprotein B (ApoB), and lipoprotein a [Lp(a)], together with reduced levels of high-density 
lipoprotein (HDLc) and apolipoprotein A-I (ApoA-I) (1-4). Several studies reported an association 
between a small size at birth and fat mass and/or components of the lipid profile in later life (5-
12), which might indicate that subjects born with a low birth weight would have an increased risk 
for developing CVD. These reports have contributed to the hypothesis that impaired fetal growth 
may be associated with abnormal metabolic and cardiovascular parameters in later life.
 Small size at birth may be due to preterm birth, poor fetal growth, or a combination of 
both. Most studies focused on subjects with a low birth weight and did not have information on 
gestational age, did not correct for it, or only included subjects born term (6-9). It is, therefore, 
difficult to determine whether the effect of a small size at birth on cardiovascular risk factors 
in later life is due to a small size for gestational age (SGA) or to prematurity. Previous research 
by Leunissen et al. (10) showed that low birth weight was no significant determinant of serum 
lipid levels in young adults born term. We, therefore, hypothesized that the previously described 
effect of a small birth size on serum lipid levels might be due to preterm birth rather than being 
born SGA.
 Approximately 7% of all Dutch newborns are born preterm (gestational age <37 wk, 
Central Bureau of Sta tistics 2007, The Netherlands). Preterm infants are frequently exposed 
to early postnatal growth restriction, glucocorticoid treatment, and stressful events. This may 
be important in the development of later organ dysfunction and adverse vascular outcome and 
could increase the effect of prematurity on fat mass and lipid levels in later life. To date, most 
long-term follow-up studies have focused on neurodevelopmental and respiratory complications 
of preterm infants (13-16), with little attention to cardiovascular outcome. Due to advances in 
neonatal care, survival of preterm and very low birth weight infants has significantly improved, 
and an increasing number of these children reach adulthood. It is, therefore, of increasing 
importance to assess the long-term effect of prematurity on determinants for CVD. 
 In line with our hypothesis that preterm birth is associated with an adverse lipid profile in 
early adulthood, we also hypothesized that being born preterm is associated with more fat mass 
because most lipid levels are influenced by the amount of fat mass. Therefore, we investigated 
the long-term effects of gestational age and particularly preterm birth on these outcome 
parameters. We also assessed whether being born SGA, in addition to preterm birth, increases 
the risk for adverse cardiovascular parameters in this group.
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Subjects and Methods
Subjects
The PREMS/PROGRAM study cohort consists of 492 healthy subjects, aged 18 to 24 yr. Preterm-
born subjects (gestational age <36 wk, PREMS study) had been admitted to the neonatal intensive 
care unit of the Erasmus University Medical Centre shortly after birth. Term subjects (gestational 
age ≥36 wk, PROGRAM study) were randomly selected from hospitals in The Netherlands, where 
they had been registered because of being born SGA [defined as birth length below -2 SD score 
(SDS)]. In addition, healthy term subjects of different schools were randomly asked to participate 
(PROGRAM study).
 The participation rate of the PREMS/PROGRAM study cohort was 79.5%. All participants 
fulfilled the same inclusion criteria: 1) age 18-24 yr; 2) Caucasian; 3) born singleton; 4) 
uncomplicated neonatal period without signs of severe asphyxia (defined as an Apgar score <3 
after 5 min), without sepsis or long-term complications of respiratory ventilation, such as bron- 
chopulmonary dysplasia; and 5) maximum duration of respiratory ventilation and/or oxygen 
supply of 2 wk during the neonatal period. Subjects with a serious neonatal complication (e.g. 
necrotizing enterocolitis, respiratory problems requiring glucocorticoids, degree 3 or more 
intraventricular hemorrhage, spastic hemiplegia or quadriplegia), an endocrine or metabolic 
disorder, chromosomal defects, syndromes or serious dysmorphic symptoms suggestive for 
a yet unknown syndrome were excluded. Subjects with a condition known to interfere with 
growth, including GH deficiency, severe chronic illness, emotional deprivation, GH treatment, 
glucocorticosteroids treatment, and radiotherapy, were also excluded.
 Data regarding gestational age and birth size were taken from hospital records and records 
from community health services and general practitioners. Information regarding socioeconomic 
status (SES), cigarette smoking, alcohol consumption, and usage of oral contraceptives was 
obtained using questionnaires. SES was determined by using educational level of the participant, 
which was assessed by the highest grade of school completed or currently participating in, and 
categorized into: 1) high (higher general secondary education or higher); 2) median (junior gen- 
eral secondary education – secondary vocational education); and 3) low education (preparatory 
middle-level vocational education or lower).
 Of the 492 participants who entered the study, 37 had incomplete data on body composition 
and lipid levels, resulting in a total number of 455 eligible subjects for analyses. There were no 
differences in anthropometric measurements between the included and excluded participants.
 Based on SDS of birth length and adult height, the subjects were also assigned to one of 
three subgroups. To increase the statistical power for subgroup comparison, the cutoff values for 
small birth size and short adult height were set at -2 SDS, and the cutoff values for normal birth 
size and normal adult height were set at -1 SDS. This resulted in a total of 269 participants who 
were included in one of the three subgroups:
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 − Subjects born SGA (birth length below -2 SDS) with a short adult height (below -2 SDS) 
(SGA-S; n=49).
 − Subjects born SGA (birth length below -2 SDS) with catch-up growth resulting in a normal 
adult height (above -1 SDS) (SGA-CU; n=85).
 − Subjects born appropriate for gestational age (AGA; birth length above -1 SDS) with a 
normal adult height (above -1 SDS) (n=135).
All participants were invited to visit the Erasmus University Medical Centre in Rotterdam, The 
Netherlands. They had been fasting for at least 12 h and had abstained from smoking and alcohol 
for at least 16 h. The center’s Medical Research Ethics Committee approved this study. Written 
informed consent was obtained from all the participants.
Anthropometry
Adult height was measured to the nearest 0.1 cm using a Harpenden stadiometer (Holtain, 
Ltd., Crymych, UK). Weight was measured to the nearest 0.1 kg on a digital scale (Servo Balance 
KA-20-150S; Servo Berkel Prior, Katwijk, The Netherlands). All anthropometric measurements 
were performed twice, and the mean value was used for analysis. Body mass index (BMI) was 
calculated by dividing weight in kilograms by the square of height in meters and rounded to the 
nearest tenth.
 
Body composition
Body composition was measured by dual-energy x-ray ab-sorptiometry (DXA, type Lunar-Prodigy; 
GE Healthcare, Chalfont St.Giles, UK). All scans were made on the same machine, and quality 
assurance was performed daily. For this type of DXA, the intra assay coefficient of variation has 
been reported to be 0.41-0.88% for fat issue and 1.57-4.49% for lean body mass (LBM) (17).
Laboratory methods
After centrifugation, all samples were kept frozen until assayed (°80C). Fasting levels of TC, 
Tg, ApoB, Lp(a), HDLc, and ApoA-I were measured. LDLc was calculated using the Friedewald 
formula: LDLc (mmol/liter)=TC -HDLc - 0.45*Tg (18). 
 TC and Tg were measured using an automated enzymatic method with the CHOD-PAP 
reagent kit and with the GPO-PAP reagent kit, respectively (Roche Diagnostics, Mannheim, 
Germany). HDLc was measured using a homogeneous enzymatic colorimetric assay (Roche 
Diagnostics); ApoA-I, ApoB, and Lp(a) were determined by rate nephelometry on the Image 
Immunochemistry System, according to the manufacturer’s instructions (Beckman Coulter, 
Mijdrecht, The Netherlands). The intraassay variations of measurements of TC, Tg, and HDLc 
were 2.9, 3.3, and 3.9%, respectively. Between-run coefficients of variation for ApoA-I, ApoB, and 
Lp(a) were 4.2, 2.8, and 6.9% at levels of 0.94, 0.53, and 0.35 g/liter, respectively .
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Statistics
To correct for gestational age, SDS for birth length and birth weight were calculated (19). To 
adjust for gender and age, SDS for adult height and adult weight were calculated (20). ANOVA 
was used to determine whether there were differences between subjects born either preterm 
or term with regard to clinical characteristics. Differences in smoking, alcohol use, SES, and oral 
contraceptive use were determined using a Χ2 test. Multiple linear regression analysis was used 
to determine differences between preterm and term subjects regarding fat mass (adjusted for 
age, gender, SES, birth length SDS, birth weight SDS, and adult height SDS) and regarding lipid 
levels (adjusted for age, gender, SES, alcohol, smoking, birth length SDS, adult height SDS, fat 
mass, and LBM). All lipid levels were log-transformed before analyses because of a skewed 
distribution. We also compared the SGA-S subjects born preterm and term, the SGA-CU subjects 
born preterm and term, and the AGA subjects born preterm and term. 
 The prevalences of raised TC levels (TC>6.5 mmol/liter), raised LDLc levels (LDLc>4.12 
mmol/liter), raised Tg level (Tg>2.0 mmol/liter), raised ApoB levels (ApoB≥1.20 g/liter), raised Lp 
(a) levels [Lp(a)>0.30 g/liter], reduced HDLc levels (HDLc<0.9 mmol/liter, males; or <1.1 mmol/
liter, females), and reduced ApoA-I levels (ApoA-I≤1.20 g/liter) were calculated for the preterm 
and term subjects. Differences in these prevalences were analyzed using a Χ2 test. 
 Multiple linear regression analysis was performed to determine the association between 
gestational age and fat mass (total fat mass, trunk fat mass, and limb fat mass). In model A, we 
entered gestational age, age, gender, birth length SDS, birth weight SDS, and adult height SDS. 
Next, we added SES, smoking, and alcohol use to model A (model B). Finally, adult weight SDS 
was added to the model, resulting in model C. By adding adult weight SDS into the model, we 
investigated the association between gestational age and fat mass, whereas adult weight SDS 
was assumed constant, thus indirectly demonstrating the association between gestational age 
and fat percentage. Oral contraceptive use was subsequently added and analyzed as a possible 
confounder only in the female subjects.
 To study the effect of gestational age on TC, LDLc, Tg, ApoB, Lp(a), HDLc, and ApoA-I, we 
first entered gestational age, age, gender, birth length SDS, birth weight SDS, and adult height 
SDS (model A). Next, we added SES, smoking, alcohol use and adult weight SDS (model B). Finally, 
adult weight SDS was replaced by LBM and fat mass to investigate the relative effect of muscle 
and/or fat mass (model C). Oral contraceptive use was then added and analyzed as a possible 
confounder in the female subjects.
 The interaction term birth length SDS*adult height SDS was added to all multiple linear 
regression models because the study group had been selected on birth length and adult height 
to ensure that the effect of these variables was modeled correctly.
To evaluate whether being born SGA had an effect on adult cardiovascular parameters in addition 
to being born preterm, preterm (yes or no) and SGA (yes or no) were added to a multiple linear 
regression model, with adjustments for possible confounders (age, gender, and SES in the 
analysis with fat mass as dependent variable; age, gender, SES, alcohol, smoking, fat mass, and 
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LBM in the analyses with lipid levels as dependent variables). Within the SGA subgroups, the 
effect of showing spontaneous catch-up growth to an adult height greater than -1 SDS (yes or no) 
was assessed by then adding catch-up growth as an independent parameter into this multiple 
linear regression analysis.
 Statistical package SPSS version 16.0 (SPSS, Inc., Chicago, IL) was used for analyses. Results 
were regarded statistically significant if the P value was <0.05.
Results
Clinical characteristics
The total study population consisted of 455 subjects. The clinical characteristics of the total study 
population, subdivided into adults born preterm vs. term, are shown in Table 1. Young adults 
born preterm had a higher birth weight SDS (P<0.001), adult height SDS (P<0.001), and adult 
weight SDS (P=0.002) than subjects born term. Mean BMI SDS was well within the normal range 
in both preterm and term subjects. The percentage of alcohol users and smokers was similar for 
preterm and term subjects, as was the SES. Females born preterm used oral contraceptives less 
frequently than those born term (P=0.036).
Preterm vs. term
Comparison of preterm and term subjects in the total study group showed that, after adjustment 
for possible confounders, preterm subjects had significantly more total fat mass (P=0.017), trunk 
fat mass (P=0.021), and limb fat mass (P=0.017) than subjects born term. However, preterm 
subjects had significantly lower Lp(a) levels (P<0.001) and higher ApoA-I levels (P<0.01) than 
term subjects. TC levels were significantly lower in preterm compared with term subjects 
(P=0.030) (Table 1).
 Table 2 shows the prevalence of lipid levels above or below the normal range in the 
preterm and term subjects. There was a significant difference in prevalence of reduced ApoA-I 
levels between the preterm (12.6%) and term (33.3%) subjects. Abnormal TC, LDLc, Tg, ApoB, 
Lp(a), and HDLc levels occurred less frequently in preterm than in term subjects. However, these 
differences did not reach significance.
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Gestational age
Using multiple linear regression analyses, we studied the effect of gestational age, as a continuous 
variable, on fat mass and lipid levels after adjustment for several confounders.
Table 2. Prevalence of abnormal lipid levels in early adulthood
Lipid levels Preterm Term P value
High TC levels  2/165 (1.2%)  7/281 (2.4%) 0.363
High LDLc levels  2/165 (1.2%) 11/277 (3.8%) 0.106
High Tg levels  7/160 (4.2%) 14/274 (4.9%) 0.743
High ApoB levels  8/159 (4.8%) 22/266 (7.6%) 0.238
High Lp(a) levels 25/142 (15.0%) 60/228 (20.8%) 0.122
Low HDLc levels 18/149 (10.8%) 35/253 (12.2%) 0.660
Low ApoA-I levels 21/146 (12.6%) 96/192 (33.3%) <0.001
Abnormal lipid levels are defined as TC >6.5 mmol/liter, LDLc >4.12 mmol/liter, Tg >2.0 mmol/liter, ApoB ≥1.20 g/
liter, Lp (a) >0.30 g/ liter, HDLc <0.9 (males) or 1.1 (females) mmol/liter, and ApoA-I ≤1.20 g/liter.
Significant P values are indicated in boldface.
Relationship between gestational age and fat mass
Gestational age was inversely associated with total fat mass (P=0.015), trunk fat mass (P=0.010), 
and limb fat mass (P=0.029), after adjustment for age, gender, birth length SDS, birth weight 
SDS, and adult height SDS (Table 3). These associations remained significant after additional 
correction for SES, smoking, and alcohol use. Adjustment for oral contraceptive use in the female 
subjects did not change these results. Within the female subjects, oral contraceptive use did not 
significantly influence the variance in fat mass (total, trunk, and limb fat mass, data not shown).
 By adding adult weight SDS to the analyses, we indirectly demonstrate the association 
between gestational age and fat percentage (see Subjects and Methods). Lower gestational 
age remained associated with a higher percentage of total fat mass (P=0.003), trunk fat mass 
(P=0.003), and limb fat mass (P=0.006).
Relationship between gestational age and lipid levels
Gestational age was not significantly associated with TC (P=0.241), LDLc (P=0.211), Tg (P= 0.227), 
ApoB (P=0.099), and HDLc (P=0.953), also after adjustment for age, gender, birth length SDS, 
birth weight SDS, adult height SDS, SES, smoking, alcohol use, LBM, and fat mass (Tables 4-6). 
Adding oral contraceptive use to the model did not change these results. Oral contraceptive use 
was, however, a significant determinant of the variance in Tg (P<0.001), ApoA-I (P=0.026), and 
ApoB (P=0.007).
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Gestational age was positively associated with Lp(a) (P=0.002) and inversely associated with 
ApoA-I (P<0.001), also after adjustment for possible confounders (model C), indicating that 
subjects with a lower gestational age had lower levels of Lp(a) and higher levels of ApoA-I.
Preterm birth and SGA
Being born SGA, in addition to preterm birth, had no effect on total fat mass (P=0.894), trunk fat 
mass (P=0.841), and limb fat mass (P=0.957). Catch-up growth to a normal height after SGA birth 
was also not an additional contributor to the variance in total fat mass (P=0.145), trunk fat mass 
(P=0.153), and limb fat mass (P=0.147).
 Furthermore, being born SGA did not additionally affect the variance in TC (P=0.142), LDLc 
(P=0.086), Tg (P=0.370), Lp(a) (P=0.397), HDLc (P=0.201), or ApoA-I (P=0.536). SGA birth did have 
a small positive effect on ApoB (P=0.034). Within the subjects who were born SGA, catch-up 
growth was not an additional contributor to the variance in Tg (P=0.904), Lp(a) (P=0.752), HDLc 
(P=0.457), and ApoA-I (P=0.993). Catch-up growth did contribute to the variance in TC (P=0.033), 
LDLc (P=0.009), and ApoB (P=0.009), in addition to being born preterm and SGA.
Discussion
Our study in 455 young adults shows that lower gestational age is associated with a higher 
percentage of total fat mass, trunk fat mass, and limb fat mass in early adulthood. In addition, 
our subgroup analysis shows that young adults born preterm have more fat mass. A shorter 
gestational age was, however, also associated with lower serum Lp(a) and higher ApoA-I levels. 
Thus, in accordance with our hypothesis, subjects born preterm are prone to develop a less 
favorable body composition later in life, but in contrast to our expectations they have a relatively 
favorable lipid profile. Being born SGA, in addition to being born preterm, had no effect on fat 
mass and most lipid levels, except for a small effect on ApoB levels.
 Body fat mass and, in particular, trunk fat mass are major risk factors for cardiovascular 
disease (21). At the age of 18-24 yr, adults born preterm had significantly more fat mass (total 
fat mass, trunk fat mass, and limb fat mass) than adults born term, although BMI SDS was within 
the normal range and was similar in both groups. Some studies showed that children born 
preterm were shorter and lighter during childhood than children born term (22,23). We could 
not confirm such results in our population of young adults. Our results are in line with previous 
research in a cohort of healthy young adults. At the age of 18-27 yr, subjects born preterm had 
significantly more total fat mass and trunk fat mass than subjects born term, measured by whole 
body magnetic resonance imaging (12). Doyle et al. (24) also described a relative increase in 
BMI in subjects born preterm before the subjects reached the age of 20 yr. It might well be that, 
under the influence of hormonal changes in puberty and adolescence, preterm subjects undergo 
a relatively large increase in fat mass. Further longitudinal follow-up studies in childhood and 
adolescence are important to confirm these findings.
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Another study found no differences in total fat mass between preterm and term subjects in 87 
young adults (5). This might be due to the fact that fat mass was estimated using bioelectrical 
impedance analysis, which is known to underestimate total body fat percentage and fat tissue 
compared with DXA (25). Another reason for the difference might be that our cohort comprised 
a larger group of preterm subjects, which enables us to find differences with more statistical 
power.
 The multiple linear regression analysis showed that the amount of fat mass was a significant 
contributor to the variance in most lipid levels. Because we showed that subjects born preterm 
had more fat mass, we expected a more adverse lipid profile. Gestational age was, however, not 
associated with TC, LDLc, Tg, ApoB, and HDLc. In our subgroup analyses, adults born preterm did 
have lower TC than those born term, but this difference is not likely to be clinically significant 
because preterm and term subjects had the same prevalence of abnormal TC levels. Our study 
was performed in young adults, and clinical manifestations of CVD do not usually occur before 
middle age. Assuming that the amount of fat mass of preterm subjects remains higher through- 
out adulthood, they might develop a more adverse lipid profile on the longer term.
 A shorter gestational age was associated with lower Lp(a) levels and higher ApoA-I levels, 
and subjects born preterm had a significantly lower prevalence of adverse ApoA-I levels (12.6%), 
compared with those born term (33.3%). This might indicate that young adults born preterm 
have a more favorable lipid profile than those born term, although their body composition seems 
to be disadvantageous. Noteworthy, Lp(a) and ApoA-I levels were the only lipids not influenced 
by adult weight SDS. This indicates that Lp(a) and ApoA-I levels are not directly influenced by fat 
or fat accumulation but are determined by other factors, like genetic factors (10,26,27).
 A relatively high percentage of our study population consisted of subjects born SGA (36.7%), 
compared with the normal population in which the prevalence of SGA is only 2.3%. This enabled 
us to study the additional effect of a small size at birth with more statistical power. In practice, 
preterm infants are more prone to impaired fetal growth than infants born term (28). We found 
no additional effect of being born SGA on the variance of fat mass and only a marginal effect 
of being born SGA on ApoB levels, whereas SGA had no effect on all other lipid levels. This is in 
accordance with our previous report by Leunissen et al. (10), who showed in subjects born term 
that fat mass of young adults born SGA was similar to fat mass of controls born AGA and that fat 
accumulation during childhood significantly determined serum lipid levels, whereas birth size did 
not. Irving et al. (11) also showed that among premature babies, those with intrauterine growth 
restriction were not measurably more disadvantaged regarding cardiovascular risk factors, e.g. 
lipid levels, than those born with birth weights AGA. This confirms our hypothesis that the 
previously described effect of small birth size on fat mass and lipid levels is due to preterm birth 
rather than being born SGA.
 Family history is a well-known independent risk factor for future abnormal lipid profiles, as 
well as for CVD (29). It would have been of additional value to include this determinant of CVD in 
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our analyses. Unfortunately, we did not have sufficient information to assess family history in our 
cohort of young adults. However, none of the subjects who fully completed the questionnaires 
mentioned a family history of hyperlipidemia, CVD, hypertension, or type 2 diabetes mellitus.
 In conclusion, in our cohort of 455 young adults, preterm birth was associated with more 
total fat mass, trunk fat, and limb fat mass, but also with a relatively favorable lipid profile. 
Further research is needed to evaluate whether or not these differences predispose subjects 
born preterm to CVD later in life. Such data are of major importance as an increasing number of 
children born preterm reach adulthood.
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Abstract 
Introduction: Both preterm birth and small birth size for gestational age (SGA) have been 
associated with an increased risk for developing cardiovascular disease (CVD), but controversies 
still exist. Our aim was to investigate the effect of preterm birth on risk factors for CVD, 
independent of birth size.
Patients and Methods: Observational study using data of 406 healthy participants aged 18 to 
24 years, from the PROGRAM/PREMS study. Associations between gestational age and systolic 
blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure, blood pressure variability, 
heart rate, Pulse Wave Velocity (PWV), and carotid Intima Media Thickness (cIMT) were studied. 
To study the differential effects of preterm and SGA birth, these parameters were also analyzed 
in subgroups born either preterm or term: young adults born SGA with short or normal adult 
stature, and young adults born appropriate for gestational age with normal adult stature.
Results: Subjects born preterm (gestational age <36 weeks) had higher unadjusted SBP, pulse 
pressure, systolic and diastolic blood pressure variability, and heart rate, but a lower DBP than 
subjects born term. Gestational age was inversely associated with SBP, pulse pressure, blood 
pressure variability, and heart rate, and positively associated with DBP, also after adjustment for 
confounders. There was no effect of gestational age on PWV and cIMT, a marker of atherosclerosis. 
Of all the CVD risk factors measured, higher pulse pressure affected cIMT the most. 
Conclusions: Young adults born preterm might have a higher risk for CVD than those born term.
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Introduction
Small size at birth has been associated with an increased risk for developing cardiovascular 
disease (CVD) in later life (1). Both preterm birth and poor fetal growth can lead to small birth 
size. Thus, in unraveling the mechanism of this association, independent effects of gestational 
age as well as small birth size for gestational age (SGA) are important to determine. 
 Increased blood pressure and arterial stiffness (quantified by Pulse Wave Velocity (PWV) 
(2-3) are major determinants of CVD, and both preterm birth and SGA birth have been related to 
these CVD risk factors (1, 4-9). 
 A recent study showed increased carotid Intima Media Thickness (cIMT), which is a measure 
of atherosclerosis (10), in subjects born preterm, however, this was restricted to those with fetal 
growth restriction (11). Furthermore, low birth weight has been associated with increased cIMT 
in young adulthood (12). Although these results were not adjusted for gestational age, it was 
shown that exclusion of young adults born preterm strengthened the association, indicating that 
the effect of small birth size on cIMT was due to SGA rather than preterm birth. In contrast, 
others showed that birth weight SDS did not associate with cIMT in young adulthood (13).
 We investigated differences between young adults born either preterm or term, using the 
following variables: systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure 
(14), blood pressure variability (15-16), heart rate (17), PWV, and cIMT. We also investigated 
the influence of gestational age on these outcomes after adjustment for several confounders, 
including birth weight SDS and birth length SDS. Additionally, we studied the differential effects 
of preterm and SGA birth on CVD risk, by subdividing the total population in clinically relevant 
groups: born small for gestational age (either preterm or term) with short (SGA-S) or normal 
adult stature (SGA-CU), and born appropriate for gestational age (either preterm or term) with 
normal adult stature (AGA).
Methods
The PROGRAM (n=323) and PREMS (n=169) study cohorts consist of 492 healthy participants, 
aged 18-24 years. The PROGRAM- and PREMS study cohorts had similar inclusion and exclusion 
criteria, study center (Erasmus University Medical Centre in Rotterdam), and measurements, the 
only difference was that the PREMS study consists of participants born preterm (gestational age 
<36 weeks). Participants were recruited from several hospitals in the Netherlands, where they 
had been registered because of their small birth size (birth length<-2SDS) (18), short stature 
(adult height<-2SDS) (19), or being born preterm. By using advertisement, healthy subjects born 
AGA were asked to participate. The participation rate of the PROGRAM/PREMS study cohort was 
79.5% (20). The study population has been previously described in detail (20-21). Birth data were 
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taken from medical records of hospitals, community health services and general practitioners. 
Information regarding socioeconomic status (SES), smoking and alcohol use was obtained 
using questionnaires. Education level of the participant was used as socioeconomic indicator 
to determine SES (22). The Medical Ethics Committee of Erasmus Medical Centre approved the 
study. Written informed consent was obtained from all participants. 
 Of the 492 participants who entered the study, 86 had incomplete data because the devices 
to measure blood pressure, cIMT and PWV were not available at all times, resulting in a total 
number of 406 eligible subjects for analyses. 
 Additionally, based on SD-scores of birth length and adult height, the subjects were assigned 
to one of three subgroups. In order to increase the statistical power for subgroup comparison, 
the cut-off values for small birth size and short adult height were set at -2 SDS, and the cut-off 
values for normal birth size and normal adult height were set at -1 SDS. This resulted in a total of 
246 participants who were included in one of the three subgroups: 
 − SGA (birth length<-2 SDS) with a short adult height (<-2 SDS)(SGA-S):n=44,
 − SGA (birth length<-2 SDS) with catch-up growth resulting in normal adult height (>-1 SDS)
(SGA-CU):n=75,
 − AGA (birth length>-1 SDS) with normal adult height (>-1 SDS)(AGA):n=127.
All participants fasted for 12 hours and abstained from smoking and alcohol for 16 hours. Height 
was measured to the nearest 0.1 cm by a Harpenden stadiometer, weight to the nearest 0.1 kg by 
a scale (Servo Balance KA-20-150S). All anthropometric measurements were performed twice; 
the mean was used for analysis. 
 Blood pressure and heart rate were measured after 10 minutes at rest, in the supine 
position, using the nondominant arm with an automatic device (Accutorr Plus, Datascope 
Corp., Montvale NJ, USA (23)) every five minutes for one hour and the mean values of these 13 
measurements were taken to reflect resting blood pressure and resting hear rate (HR). Measuring 
blood pressure using an automatic device has many advantages, however some factors influence 
the measurement accuracy such as the underlying algorithms used and size and material of 
the cuff (24). The device used in the present study has been validated by the Association for 
the Advancement of Medical Instruments (AAMI) and the British Hypertension Society (BHS), 
concluding that the device gives accurate measurements in greatest agreement with the mercury 
standard (25). The 13 blood pressure measurements were also used to calculate the coefficient 
of variation (15-16). Pulse pressure was calculated as the difference between mean systolic and 
diastolic blood pressure (14). 
 Carotid-femoral PWV was measured in supine position using SphygmoCor (AtCor Medical, 
Sydney Australia) (26). A pressure tonometer was used to simultaneously record carotid pulse 
wave and ECG. The femoral pulse wave and ECG were also recorded. Distance travelled by the 
pulse wave was determined by measuring the distances from sternal notch to the femoral 
location and from sternal notch to the carotid location of pulse wave recording (27).
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Carotid IMT was measured in supine position by recording of ultrasonographic images of both left 
and right carotid artery, using one 7.5 MHz linear array transducer (ATL Ultramark IV, Advanced 
Tech. Laboratories, Bethel Washington, USA) (28). On the R-wave of the electrocardiogram, 
three longitudinal images of the near and far wall of the common carotid artery were frozen 
and stored on videotape. These frozen images were digitalized and displayed on the screen of a 
computer using a frame grabber (VP 1400-KIT-512-E-AT, Imaging Technology). The common cIMT 
was determined as the mean of the mean near and far wall measurements of both the left and 
right side common carotid artery (28). 
Statistical analysis
SD-scores for birth length and birth weight were calculated to correct for gestational age and 
sex (18). SD-scores for adult height, and adult weight were calculated to correct for sex, and 
age(19). Variables were log-transformed (natural logarithm) if not normally distributed. ANOVA 
was used to determine if there were differences between participants born either preterm or 
term. Using the 13 blood pressure measurements, the coefficient of variation (CV) was calculated 
to determine the within-subject variation in SBP and DBP with time (blood pressure variability)
(15,29).
 Multiple linear regression (MR)-analysis was performed to determine the association of 
gestational age with SBP, DBP, pulse pressure, blood pressure variability, HR, PWV, and cIMT 
independent of birth size. In all MR-models, adjustments were made for birth length SDS, birth 
weight SDS, adult height SDS, age, sex, SES, smoking, alcohol use, and the interaction term 
birth length SDS*adult height SDS because the study group had been selected on birth length 
and adult height (Model A). To study the association with SBP, DBP, pulse pressure, and blood 
pressure variability, we additionally adjusted for weight SDS (model B), and heart rate (model C). 
To study PWV, we additionally adjusted for mean arterial pressure (MAP) (model B), weight SDS, 
the interaction term sex*weight SDS and age*weight SDS (model C), and heart rate (model D). 
To study cIMT, we additionally adjusted for artery diameter (model B), and weight SDS (model 
C). We tested which parameter (SBP, DBP, pulse pressure, blood pressure variability, HR, PWV) 
was the most important determinant of cIMT, by adding the parameters alternately to the final 
cIMT-model. All regression coefficients are presented as a percentage for better interpretation of 
the results. A positive value indicates that the dependent variable is increased by that % for every 
unit increase of the independent variable.
 ANCOVA was used to determine differences in blood pressure among the subgroups 
corrected for age and sex (model 1), and additionally adjusted for alcohol use, smoking, SES, 
and weight SDS (model 2). In blood pressure analyses, heart rate was added to model 2. In HR 
analyses, systolic blood pressure was added to model 1. In PWV analyses, MAP and HR were 
added to model 1, and height SDS was added to model 2 (model 3). In cIMT analyses, artery 
diameter was added to model 1. AGA subjects born term served as reference group and SGA-S 
preterm, SGA-S term, SGA-CU preterm, SGA-CU term, and AGA preterm were added as dummy 
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variables. Statistical package SPSS version 15.0 (SPSS, Inc., Chicago, IL) was used for analyses. 
Results were regarded statistically significant if p was <0.05. 
Results
The clinical characteristics of the total study population are shown in Table 1. Young adults born 
preterm had higher unadjusted SBP (p=0.007), pulse pressure (p<0.001), systolic and diastolic 
blood pressure variability (p=0.002, and p<0.001 respectively), and heart rate (p<0.001) than 
subjects born term. Unadjusted DBP was lower in subjects born preterm (p<0.001). 
 Gestational age was inversely associated with SBP (p=0.026) and pulse pressure (p=0.001) 
after correction for age, sex, SES, smoking, alcohol use, adult height SDS, and birth size. These 
associations remained significant after additional correction for adult weight SDS (Table 2). In 
contrast with the association between gestational age and pulse pressure, which remained 
significant after additional correction for heart rate, the association of gestational age with SBP 
disappeared after correction for heart rate. Heart rate on itself was positively associated with 
SBP (p<0.001) (Table 2). 
 Gestational age was positively associated with DBP after correction for age, sex, SES, 
smoking, alcohol use, adult height SDS and birth size (p=0.001) (Table 2). This association 
remained significant after additional adjustment for weight SDS and heart rate (p<0.001), which 
were both positively associated with DBP (p<0.001).
 Lower gestational age was associated with a higher coefficient of variation of both systolic 
(β(%)=-1.67, p=0.003, adj. R2=0.058) and diastolic blood pressure (β(%)=-2.85, p<0.001, adj. 
R2=0.149), after adjustment for age, sex, birth length SDS, birth weight SDS, adult height SDS, 
SES, smoking, alcohol use, heart rate, and weight SDS (data not shown). 
 In MR-analyses, gestational age was inversely associated with heart rate after adjustment 
for age, sex, birth size, adult height SDS, SES, smoking, and alcohol use (β(%)=-0.86, p<0.001, adj. 
R2=0.176). This association remained significant after additional adjustment for weight SDS and 
SBP (β(%)=-0.76, p<0.001, adj. R2=0.213) (data not shown).
 After adjustments, gestational age was not significantly associated with PWV (Table 3). 
Adult height SDS showed a significant positive association with PWV (p=0.029) after adjustment 
for weight SDS. Smoking, higher mean arterial pressure, and higher heart rate, were also related 
to a higher PWV. 
 Lower gestational age showed a trend towards lower cIMT after adjustment for age, sex, 
SES, smoking, alcohol use, adult height SDS, and birth size (p=0.074) (Table 3). However, this 
disappeared after adjustment for artery diameter, which was positively associated with cIMT. 
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Table 1. Unadjusted clinical characteristics of the total study population and subgroups
Total study population Subgroups
SGA-S SGA-CU AGA
Preterm 
(n=163)
Term 
(n= 243)
Preterm 
(n=9)
Term 
(n=34)
Preterm 
(n=31)
Term 
(n=44)
Preterm 
(n=63)
Term 
(n=64)
Male/female # 83/80§ 92/151 5/4 10/24 15/16 17/27 37/26 26/38
Age (yrs) 20.8(1.7) 20.9(1.7) 21.6(1.8) 20.6(1.7) 20.4(1.9)§ 21.4(1.4) 21.0(1.6) 20.7(1.8)
Gestational age 
(wks)
32.0(2.2)† 39.2(1.7) 32.3(1.5)† 39.3(1.6) 32.3(2.1)† 38.3(1.6) 32.3(2.4)† 39.4(1.6)
Birth length  
SDS
-1.22(1.9) -1.46(1.5) -3.58(1.0) -2.99(0.9) -3.16(0.8) -2.85(0.8) 0.38(0.9) 0.14(0.7)
Birth weight  
SDS
-0.42(1.8)† -1.12(1.4) -2.49(0.9) -2.02(0.9) -2.11(1.1) -2.36(0.7) 0.79(1.1)§ 0.08(1.2)
Adult height  
SDS
-0.42(1.0)† -1.03(1.4) -2.31(0.3) -2.61(0.6) -0.10(0.6) -0.11(0.8) 0.13(0.6) 0.38(0.9)
Adult weight 
SDS
-0.28(1.2)‡ -0.63(1.4) -1.08(1.2) -1.50(1.6) -0.32(1.2) 0.21(1.1) 0.27(0.8) 0.10(0.9)
SBP(mmHg)* 112.3(8.0)§ 110.0(9.0) 109.2(6.6) 107.8(10.2) 113.4(7.2) 112.4(10.2) 113.1(8.2)‡ 110.1(7.2)
DBP(mmHg) 63.3(5.3)† 66.1(5.9) 58.2(3.3)§ 66.2(8.0) 64.5(5.2) 66.6(6.1) 63.6(5.4)§ 66.1(5.0)
PP(mmHg)* 48.9(6.2)† 43.8(5.8) 51.0(6.1)† 41.7(5.2) 48.9(6.0)‡ 45.8(6.7) 49.5(6.1)† 43.9(5.5)
CV SBP(%)* 5.17(1.8)§ 4.77(2.7) 5.90(1.9) 5.49(4.4) 5.07(1.7) 4.42(1.8) 5.00(1.5) 4.62(2.1)
CV DBP(%)* 9.77(3.2)† 7.98(3.7) 9.00(2.1) 8.36(3.1) 9.64(2.8)§ 7.87(3.1) 9.21(3.0)§ 7.59(4.3)
HR (beats/
minute)
70(9.1)† 65(9.0) 67(9.1) 71(9.6) 72(11.0)§ 65(9.1) 69(8.6)§ 64(8.4)
PWV (m/sec)* 7.60(1.0) 7.59(0.9) 8.00(0.8) 7.16(1.0) 7.65(1.1) 7.62(1.1) 7.67(0.9) 7.76(1.2)
cIMT (mm)* 0.52(0.1) 0.52(0.05) 0.52(0.1) 0.50(0.05) 0.52(0.1) 0.53(0.1) 0.53(0.1) 0.52(0.05)
Supplement
GA Median 
(IQR)
32(29-34) 40(38-40) 32(32-34) 40(38-41) 33(31-34) 38(37-40) 34(32-36) 40(40-41)
BMI 22.2(3.4) 22.4(3.5) 23.5(3.6) 23.1(5.0) 21.5(3.7) 23.2(3.6) 22.7(2.7) 21.8(2.8)
Alcohol users 
(%)#
84.5‡ 75.7 77.8 76.5 80.7 80.0 88.9 78.1
Smokers (%)# 27.0 25.5 22.2 20.6 19.4 35.0 27.0 20.3
SES(%) 1 13.0 9.4 14.3 13.3 14.3 15.6 7.5 3.2
 2 30.5‡ 20.8 28.6 33.3 39.3 21.9 26.4§ 6.5
 3 56.5 69.8 57.1 53.3 46.4 62.5 66.0 90.3
MAP(mmHg)* 83.4(7.3) 83.3(7.7) 81.7(5.2) 81.9(8.2) 84.0(7.7) 86.3(9.4) 84.4(7.4) 83.0(5.8)
AD (mm) 6.66(0.4) 6.66(0.5) 6.49(0.4) 6.38(0.4) 6.65(0.4) 6.76(0.4) 6.77(0.4) 6.79(0.5)
cIMT/AD 0.08(0.01 0.08(0.01) 0.08(0.01) 0.08(0.01) 0.08(0.01) 0.08(0.01) 0.08(0.01) 0.08(0.01)
Values are given as means (SD). GA: gestational age, SDS= standard deviation score, SBP= systolic blood pressure, 
DBP= diastolic blood pressure, PP= pulse pressure, CV= Coefficient of Variation, HR= heart rate, PWV= Pulse Wave 
Velocity, cIMT= carotid Intima Media Thickness. 
*log transformed for ANOVA, # Chi-square test used to determine differences between subjects born preterm and 
term. 
†: p<.001 compared to term (same subgroup), ‡: p<.05 compared to term (same subgroup), §: p<.01 compared to 
term (same subgroup)
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Because gestational age had an effect on several markers that have been previously associated 
with atherosclerosis, we tested which marker was the most important determinant of cIMT, by 
adding the markers alternately to model C (data not shown). The effects of SBP (β(%)=0.16, 
p=0.002, adj.R2=0.198), DBP (β(%)=0.02, p=0.818, adj.R2=0.172), pulse pressure (β(%)=0.48, 
p<0.001, adj.R2=0.228), SBP variability (β(%)=0.015, p=0.475, adj.R2=0.174), DBP variability 
(β(%)=0.28, p=0.072, adj.R2=0.181), HR (β(%)=-0.06, p=0.352, adj.R2=0.176), and PWV (β=-0.62, 
p=0.259, adj.R2=0.172) on cIMT were determined. The model with the highest adjusted R2, thus 
explaining the largest proportion of variation in cIMT, was the model including pulse pressure.
 Unadjusted differences between the subgroups are shown in Table 1. Comparisons of 
preterm and term SGA-subgroups, after adjustment for age, sex, alcohol use, smoking, SES, heart 
rate and weight SDS, showed that SGA-S subjects born preterm had a significantly lower diastolic 
blood pressure (p=0.002), and a higher pulse pressure (p=0.016) than those born term. Also, 
SGA-CU subjects born preterm had a lower diastolic blood pressure (p=0.046), and a higher pulse 
pressure (p=0.028) and systolic and diastolic blood pressure variability (p=0.035 and p=0.004 
respectively) than those born term. There were no significant differences in systolic blood 
pressure between preterm and term SGA-subgroups. 
 After adjustment for age, sex, alcohol use, smoking, SES, systolic blood pressure, and weight 
SDS, SGA-CU subjects born preterm had a higher heart rate than those born term (p=0.009). 
There was, however, no significant difference in heart rate between SGA-S subjects born preterm 
or term. After adjustment for confounders, PWV and cIMT did also not differ significantly 
between subjects born preterm or term, in any of the subgroups.
 Table 4 shows comparisons of systolic blood pressure, diastolic blood pressure, pulse 
pressure, blood pressure variability, heart rate, PWV, and cIMT of the subgroups after adjustment 
for possible confounders, with AGA subjects born term as reference group. In the final model, all 
preterm subgroups had a significantly lower diastolic blood pressure, but higher pulse pressure 
and diastolic blood pressure variability than the reference group. After correction, there were 
no differences in systolic blood pressure variability and cIMT. SGA-CU and AGA subjects born 
preterm had a higher heart rate than the reference group (AGA, born term). SGA-S and SGA-CU 
subjects born term had a lower PWV than the reference group, but this significant difference 
disappeared after correction for adult height SDS. 
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Discussion
Higher blood pressure in adults born preterm than in healthy controls has been reported (30). 
Also in the present study lower gestational age was associated with higher systolic blood pressure, 
but this disappeared after adjustment for heart rate. These findings suggest that the reported 
elevated systolic blood pressure in subjects born preterm is associated with an increased heart 
rate, indicating that both might share an underlying determinant. The mechanisms underlying 
these associations remain unknown (31), but might be explained by preterm birth being 
associated with an increased cardiac output, which might eventually lead to hypertension (32).
In contrast, we showed a lower diastolic blood pressure in young adults born preterm, which 
remained significant after adjustment for several confounders. Lower diastolic blood pressure 
has been associated with less risk for CVD (33), although this was controversial in other studies 
(34). 
 To our knowledge, we are the first to report an increased pulse pressure in young adults 
born preterm. This new finding is in line with a study showing an inverse association between 
gestational age and pulse pressure in children (35). Elevated pulse pressure has been associated 
with increased risk for atherosclerosis, already in early adulthood (14,33). This was confirmed 
by our study showing that of all determinants of CVD examined, the effect of pulse pressure on 
cIMT was most pronounced, in contrast to the non-significant effect of DBP on cIMT. In addition, 
variability of systolic and diastolic blood pressure was higher in participants born preterm. Higher 
variability of blood pressure in time has also been associated with CVD (15-16). 
 Although one would expect a lower heart rate in combination with a higher pulse pressure, 
young adults born preterm had a higher heart rate than those born term. This finding is supported 
by previous studies (36-38). Johansson et al. hypothesized that an increased heart rate could be 
ascribed to altered sympathoadrenal function in subjects born small, either preterm or SGA (38). 
In the present study, higher heart rate was only found in subjects born preterm, regardless of 
birth weight. This implies that there is an effect of preterm birth on heart rate, rather than an 
effect of SGA birth. Determination of resting heart rate is of importance since it is associated with 
CVD (17). Unfortunately, the present study does not include tests to determine neural regulatory 
mechanisms. For future research it would be interesting to carry out spectral analyses in young 
adults born preterm, in order to determine whether the increased heart rate and blood pressure 
variability are due to sympathovagal imbalance (39-40). 
 We did not find an association of preterm birth with PWV. Adult height SDS was, however, 
positively associated with PWV. This association also explains the difference in PWV between 
SGA-S subjects born term and AGA subjects born term, as that difference disappeared after 
correction for height SDS. Only limited studies investigated the association between adult height 
SDS and PWV. One study showed a positive association between height and PWV in healthy 
children (41). 
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There was also no effect of preterm birth on cIMT. Previous studies reported controversial results 
regarding the association of cIMT with gestational age, preterm birth, and birth size (12-13). 
These studies, however, did not adjust for artery diameter, which is likely to be a confounder in 
the relationship of gestational age and birth size with cIMT. Also, it might well be that an effect 
of gestational age on cIMT will arise at an older age.
 The great contrasts in birth size and adult stature in our study population enabled 
performing comparisons of clinically relevant subgroups. These comparisons showed that the 
effect of preterm birth on CVD risk can not be ascribed to SGA birth and/or catch up growth. 
We found significant differences in DBP, pulse pressure, and DBP variability, between the 
preterm subgroups and term AGA controls, irrespectively of SGA birth. The preterm groups had 
a significantly higher resting heart rate, except for the preterm SGA-S subgroup. There were no 
differences in CVD risk parameters between the SGA-groups born term and the healthy controls. 
 We acknowledge that the Datascope Accutorr Plus to determine blood pressure during one 
hour uses an algorithm to compute systolic and diastolic blood pressure. Although it has shown 
to be in greatest agreement with the mercury standard, this should be taken into account. Future 
studies are warranted to reproduce our results using directly measured systolic and diastolic blood 
pressure. We also acknowledge that our study population consists of subjects without serious 
postnatal complications and did not include extreme prematurely born subjects. Whether our 
results can be generalized to subjects with complications, such as broncho-pulmonary dysplasia, 
requires further research. Furthermore, it would be of additional value to include family history, 
as a risk factor of atherosclerosis, in our analyses. Unfortunately, we did not have sufficient 
information to assess family history in our cohort of young adults. However, none of the subjects 
who fully completed the questionnaires mentioned a family history of cardiovascular disease. 
 Our data show that young adults born preterm might have a higher risk to develop CVD 
due to a higher systolic blood pressure, resting heart rate, and a higher pulse pressure and blood 
pressure variability in time. Although we show that young adults born preterm have a lower 
diastolic blood pressure than adults born term, the lower diastolic blood pressure contributes 
to an increased pulse pressure in these subjects. Because the prevalence of preterm birth and 
survival is rapidly increasing, our results are of clinical relevance for an increasing number of 
subjects and are thus of major importance for public health.
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Abstract
Objective: Previous studies showed conflicting data on the effect of prematurity on bone mineral 
density (BMD) in infants and children. Only a few studies investigated the long-term effects of 
prematurity on BMD in early adulthood. The objective of our study was to assess the long-term 
effects of preterm birth on BMD of the total body (BMDTB), lumbar spine (BMDLS) and bone mineral 
apparent density of the LS (BMADLS).
Design: Cross-sectional study.
Methods: It consists of two hundred and seventy-six healthy subjects without serious postnatal 
complications, aged 18-24 years. The contribution of gestational age to the variance in BMD in 
young adulthood and the differences in BMD between 151 subjects born preterm (median 
gestational age 32.2 weeks (interquartile range (IQR) 30.3-34.0)) and 125 subjects born at term 
(median gestational age 40.0 weeks (IQR 39.0-40.0)) were investigated. BMD was determined by 
dual-energy X-ray absorptiometry. 
Results: There were no significant linear correlations between gestational age and BMDTB (r=0.063, 
P=0.30), BMDLS (r=0.062, P=0.31) and BMADLS (r=0.069, P=0.26). Also after adjustment for possible 
confounders, gestational age was no significant contributor to the variance in BMDTB (P=0.27), 
BMDLS (P=0.91) and BMADLS (P=0.87). No significant differences were found between preterm and 
term subjects with regard to BMDTB, BMDLS and BMADLS.
Conclusion: In our cohort of 276 young adults, aged 18-24 years, gestational age was not a significant 
determinant in the variance of BMD. Preterm birth without serious postnatal complications is not 
associated with a lower BMD in young adulthood.
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Introduction
Decreased mineralization of osteoid tissue during the early postnatal period is a known complication 
of very low birth weight and/or prematurely born infants (1-3). It comprises a variety of disturbances 
ranging from mild undermineralization to frank radiological rickets with fractures (4). Preterm 
infants are at an increased risk of low bone mineral density (BMD) as bone mineralization, along 
with calcium and phosphorus accretion, mainly occurs during the third trimester of pregnancy (5).
 Previous studies showed conflicting data on the effect of preterm birth on BMD in infants 
and children. Prematurity, irrespective of birth weight, was found to be associated with lower BMD 
in infancy and early childhood (1,6-9). In contrast, other studies in young children could not show 
differences in BMD due to prematurity (2,10).
 Owing to advances in neonatal care, survival of preterm and very low birth weight infants 
has significantly improved and an increasing number of these children reach adulthood. In 2007, 
the preterm birth rate in the United States was 12.7%, which corresponds with ~550.000 preterm 
births per year (11). Moreover, this percentage is about 20% higher than the preterm birth rate in 
1990 (11). It is, therefore, of increasing importance to assess the effect of prematurity on BMD in 
adulthood. Previous studies investigated the long-term effects of low birth weight and growth on 
BMD (12-20), but very few have studied the specific contribution of the duration of gestation on 
later BMD (14,21).
 BMD in later life depends largely on the peak bone mass achieved in early adulthood and the 
subsequent bone loss (22). A high peak bone mass provides a larger reserve later in life (22,23). 
Osteoporosis is an important and increasing cause of morbidity and mortality in the developed 
countries. It is characterized by low bone mass, deterioration of bone tissue and disruption of bone 
architecture, compromised bone strength and an increase in the risk of fracture (24). According 
to the WHO diagnostic classification, osteoporosis is defined by BMD at the hip or spine that is 
≤2.5 SDS below the young normal mean reference population (24). Since early prevention of 
osteoporosis is likely to be more successful than treatment of an already established disorder, it is 
essential to identify potential risk factors.
 We hypothesized that prematurity is associated with lower BMD in early adulthood. Therefore, 
the aim of our study was to assess the long-term effects of gestational age and particularly preterm 
birth on BMD in a large group of young adults.
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Subjects and methods
Subjects
This study investigated a cohort of 276 healthy subjects, aged 18-24 years. Subjects born preterm 
(gestational age <36 weeks, n=151) had been admitted to the neonatal intensive care unit of the 
Erasmus University Medical Centre shortly after birth. In total, 37.7% of all preterm subjects were 
born small for gestational age. Term controls of similar age (gestational age ≥36 weeks, n=125) 
were randomly asked to participate from different educational institutes.
 All subjects fulfilled the same inclusion criteria: 1) age 18-24 years, 2) adult pubertal stage, 
3) Caucasian, 4) born singleton, 5) a neonatal period without signs of severe asphyxia (defined as 
an Apgar score below 3 after 5 min) or long-term complications of respiratory ventilation, such as 
bronchopulmonary dysplasia, 6) maximum duration of respiratory ventilation and/or oxygen supply 
of 2 weeks in the neonatal period. Subjects with a serious neonatal complication (e.g. necrotizing 
enterocolitis, degree 3 or more intraventricular haemorrhage, spastic hemiplegia or quadriplegia), 
an endocrine or metabolic disorder, chromosomal defects, syndromes or dysmorphic symptoms 
suggestive for a yet unknown syndrome were excluded. Subjects with a condition known to interfere 
with growth, including GH deficiency, severe chronic illness, emotional deprivation, GH treatment, 
glucocorticosteroid treatment and radiotherapy were also excluded. Birth data were taken from 
hospital records, and records from community health services and general practitioners.
 The Medical Research Ethics Committee of Erasmus University Medical Centre, Rotterdam, 
The Netherlands, approved this study. Written informed consent was obtained from all the 
participants.
Methods
Anthropometry
Adult height was measured in the upright position to the nearest 0.1 cm using a Harpenden 
stadiometer (Holtain Ltd, Crymmyth, UK). Weight was measured to the nearest 0.1 kg on a digital 
scale (Servo Balance KA-20-150S). All anthropometric measurements were performed twice, and 
the mean value was used for analysis.
Bone mineral density
Bone mass of the total body (TB), lumbar spine (LS), lean body mass (LBM) and fat mass (FM) were 
measured by dual-energy X-ray absorptiometry (DXA, type Lunar-Prodigy, GE Healthcare, Chalfont 
St Giles, UK). All scans were made on the same machine, and quality assurance was performed 
daily. The coefficient of variation (CV) was 0.5% for total body BMD and 1.0% for spine BMD (25-
27). The CV for lean mass and FM has been reported to be 0.7 and 1.2% respectively (25,26).
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To adjust for differences in bone size, we calculated bone mineral apparent density of the LS 
(BMADLS) (g/cm
3) with the model BMADLS=BMDLS * (4/(π * width)) (28). Width was the mean width 
of the second to fourth lumbar vertebral body. This model was validated by in vivo volumetric data 
obtained from magnetic resonance imaging of the lumbar vertebrae.
Questionnaire
All subjects completed a structured questionnaire, which included questions on socioeconomic 
status of the participants and their parents, cigarette smoking, alcohol consumption and usage 
of oral contraceptives. Socioeconomic status was determined by using educational level of the 
participant, which was assessed by the highest grade of school completed or currently participating 
in, and categorized into 1) high (higher general secondary education or higher), 2) median (junior 
general secondary education – secondary vocational education) and 3) low education (preparatory 
middle-level vocational education or lower).
Statistical analysis
Clinical characteristics are expressed as median (interquartile range). Birth weight and length 
were adjusted for gestational age and gender (29), and baseline data in young adulthood were 
adjusted for age and gender (30). BMD data are expressed as mean (S.D.). SDSs for BMDTB, BMDLS 
and BMADLS were calculated using reference data of Boot et al. (31).
 Independent samples t-tests were used to evaluate differences in clinical characteristics 
between preterm and term subjects. To test for linear relationships between gestational age and 
BMDTB, BMDLS and BMADLS, Pearson’s correlation coefficient was used. The long-term effect of 
gestational age on BMDTB, BMDLS and BMADLS in young adulthood was analysed using multiple 
regression analyses, corrected for possible confounders (gender, age, birth weight SDS, birth length 
SDS, adult height SDS, LBM and FM). The interaction term birth length SDS * adult height SDS was 
added to the multiple regression model to ensure that the effect of these variables was modelled 
correctly.
 To determine differences between preterm and term subjects with regard to BMD, multiple 
regression analysis was used with correction for age and gender and subsequently also with 
correction for gender, age, birth weight SDS, birth length SDS, adult height SDS, LBM and FM.
 Results were regarded statistically significant at P<0.05. Statistics were performed using the 
computer Statistical Package for Social Science (SPSS version 16.0; SPSS, Inc., Chicago, IL, USA).
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Results
Clinical characteristics
Table 1 shows the baseline characteristics of the study group. The total group of 276 subjects had a 
median age of 20.9 years. Besides the obvious difference in gestational age, preterm subjects had 
a lower birth length SDS than term subjects.
Table 1. Clinical characteristics. 
Total group Preterm Term
n 276 151 125
Gender (M/F) 119/157 76/75 43/82
Gestational age (weeks) 34.9 (32.0 to 40.0) 32.2 (30.3 to 34.0)* 40.0 (39.0 to 40.0)
Birth length SDS -0.6 (-1.7 to 0.3) -1.1 (-2.8 to 0.3)* -0.4 (-1.3 to 0.2)
Birth weight SDS -0.3 (-1.6 to 0.6) -0.3 (-2.1 to 0.8) -0.3 (-1.2 to 0.4)
Age (years) 20.9 (19.6 to 22.3) 21.0 (19.7 to 22.3) 20.6 (19.4 to 22.4)
Adult height SDS -0.3 (-1.2 to 0.3) -0.3 (-1.1 to 0.2) -0.4 (-1.5 to 0.5)
Adult weight SDS -0.3 (-1.0 to 0.3) -0.2 (-0.9 to 0.4) -0.4 (-1.0 to 0.3)
*P<0.001 between preterm and term. All values are given as median (interquartile range)
BMD and gestational age
There were no significant linear correlations between gestational age and BMDTB (r=0.063, P=0.30), 
BMDLS (r=0.062, P=0.31) and BMADLS (r=0.069, P=0.26). Multiple regression analyses showed that 
gestational age was not a significant contributor to the variance in BMDTB (P=0.27, R
2=0.370), BMDLS 
(P=0.91, R2=0.165) and BMADLS (P=0.87, R
2=0.262), after adjustment for age, gender, birth weight 
SDS, birth length SDS, adult height SDS, LBM and FM as additional independent variables.
 Furthermore, SDSs of BMD of the LS were not significantly correlated with gestational 
age (BMDLS SDS: r=0.069, P=0.25 and BMADLS SDS: r=0.031, P=0.61), whereas BMDTB SDS was 
significantly correlated with gestational age (r=0.137, P=0.023). However, after adjustments for 
possible confounders, this correlation disappeared (BMDTB SDS (P=0.28, R
2=0.290), BMDLS SDS 
(P=0.941, R2=0.175) and BMADLS SDS (P=0.815, R
2=0.064)).
 Further analysis showed that adult weight, specified as LBM and TB FM, was an important 
determinant of BMD in young adulthood, regardless of size at birth and gestational age. LBM was 
significantly associated with BMDTB (β=0.007, P<0.001) and BMDLS (β=0.008, P<0.001). FM was 
also associated with BMDTB (β=0.002, P<0.001) and BMDLS (β=0.002, P=0.08).
 In addition, we evaluated the possible confounding effects of socioeconomic status, smoking, 
alcohol and the usage of oral contraceptives on these associations. The socioeconomic status was 
low in 8.8%, median in 22.6% and high in 68.8% of all subjects, and 22.8% of all subjects smoked. 
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Of all subjects reporting alcohol consumption (80.8%), 28.6% had an alcohol consumption ≥5 units/
week. None of these factors had a significant influence on the BMD (TB and LS) outcomes.
BMD in preterm versus term subjects
No significant differences were found between preterm and term subjects with regard to BMDTB, 
BMDLS and BMADLS after correction for age and gender (Table 2). Even after additional adjustment 
for significant independent variables like birth length SDS, adult height SDS, birth weight SDS, LBM 
and FM, BMD outcomes did not significantly differ between preterm and term subjects.
Table 2. Bone mineral density in young adults born preterm vs term. 
Total group  
(n=276)
Preterm  
(n=151)
Term  
(n=125)
P value* P value†
Total body
BMDTB (g/cm
2) 1.17 (0.09) 1.17 (0.08) 1.18 (0.10) 0.127 0.429
BMDTB SDS -0.50 (0.87) -0.59 (0.83) -0.40 (0.91) 0.184 0.534
Lumbar spine
BMDLS (g/cm
2) 1.20 (0.13) 1.20 (0.13) 1.21 (0.13) 0.462 0.878
BMDLS SDS -0.45 (0.80) -0.49 (0.82) -0.39 (0.78) 0.467 0.997
BMADLS (g/cm
3) 0.37 (0.04) 0.37 (0.05) 0.37 (0.04) 0.918 0.751
BMADLS SDS -0.52 (0.93) -0.55 (0.99) -0.49 (0.84) 0.879 0.651
*Preterm vs term; P values are given after correction for age and gender. †Preterm vs term; P values are given after 
correction for age, gender, birth length SDS, adult height SDS, birth weight SDS, LBM and fat mass. All values are given 
as mean (SDS).
Discussion
Our study in 276 young adults showed that gestational age was not a significant contributor to 
the variance in BMD (BMDTB and BMDLS) and BMAD (BMADLS) in young adulthood. In addition, 
our subgroup analysis did not show differences between subjects born preterm or term. Thus, in 
contrast to our hypothesis, preterm birth was not associated with lower BMD in early adulthood.  
 Peak bone mass is an important determinant of BMD in later life, but the exact age at which 
peak bone mass is reached is not well established. Recent data show that peak bone mass is 
probably attained by the mid-twenties (32). We are one of the first to investigate BMD in subjects 
born preterm at a mean age of 21 years, thus around the age of reaching peak bone mass. Our 
results are, therefore, important for the evaluation of the long-term consequences of preterm 
birth.
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Our subgroup analysis showed no differences in BMD between subjects born preterm or term. 
Dalziel et al. investigated a cohort of 174 adults (mean age 31 years) whose mothers had 
participated in a randomized trial of antenatal betamethasone treatment. Although the main aim 
of the study was to determine the effect of maternal betamethasone usage on later BMD, they also 
showed that prematurity had no effect on peak bone mass (21). Hamed et al. showed that, in a 
cohort of 230 women (aged 20-23 years), BMD was not influenced by prematurity (14), although in 
that study no adjustments for possible confounders (e.g. LBM, FM or weight) were made and the 
cohort consisted of female subjects only.
 Weiler et al. (33) showed that preterm born adolescents had a lower bone mineral content 
(BMC) than those born at term. However, after correction for adult height and weight, these 
differences disappeared, indicating that the effect of gestational age on BMC was largely influenced 
by adult body size.
 Previous studies in infancy and early childhood showed differences in BMD between 
preterm and term subjects (1,6,7,9), but we could not confirm such results in our young adults. 
One explanation might be that there was a catch-up in bone mineralization during infancy and 
childhood (34), but to prove this hypothesis, prospective longitudinal research in preterm and term 
subjects is mandatory.
 A relative high percentage of our premature study population consisted of subjects born 
small for gestational age (SGA; 37.7%), compared to the normal population in which the prevalence 
of SGA is only 2.3%. In clinical practice, the majority of children born SGA are born preterm. 
Furthermore, our study comprises a relatively healthy population. Subjects with, for example, a 
complicated neonatal period were excluded from our analysis, and it might be that such subjects 
have a higher risk of lower BMD.
 BMD was assessed for TB and LS. As there are differences in cell biology between these two 
sites (35,36), gestational age and/or prematurity could have different effects on BMDTB and BMDLS. 
Despite these differences, gestational age was no significant determinant of both BMDTB and 
BMDLS. Furthermore, it is important to realize that bone density is just one aspect of bone quality, 
as bones are complex three-dimensional structures (37).
 Analysis of BMD showed that prematurity and also birth size had no long-term consequences 
on BMD. Instead, adult weight, LBM and TB FM were important determinants of BMD in young 
adulthood. So it seems important to ensure that appropriate growth and nutrition are maintained 
throughout childhood and adolescence. Although our data are reassuring, there is no guarantee 
that BMD will remain normal when subjects become older. Longer term follow-up is, therefore, still 
warranted.
 DXA was used to assess BMD, as it is the most commonly used technique for BMD assessment 
because of low radiation exposure, great precision and accuracy, and short scanning time (6-10 
min). Additionally, DXA performs whole body rather than slice measurements (CT) (31,38). A 
shortcoming of DXA is that it measures bone in two dimensions providing only an estimation of 
bone density. BMD is obtained by dividing BMC (g) by the projected bone image (area in cm2). 
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BMD is, therefore, dependent on bone size, and this might lead to erroneous interpretations of 
BMD values. A widely used and validated model to correct for bone size is BMAD (volumetric 
BMD) (22,28,39). For that reason, we added BMADLS as one of the parameters reflecting bone 
mineralization.
Conclusions
In conclusion, in a cohort of 276 young adults, gestational age was not a significant determinant in 
the variance of BMD (TB and LS). BMD was not adversely affected in young adults born moderately 
preterm. Thus, in contrast to our hypothesis, preterm birth without postnatal complications is not 
associated with a lower BMD in young adulthood. These findings are of major importance as an 
increasing number of preterm born subjects reach adulthood.
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Chapter 9
General discussion
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This thesis describes several risk factors for adult diseases in two conditions associated with small 
size at birth: SGA and preterm birth. The first part consists of studies in SGA children with short 
stature, treated with growth hormone. The second part focuses on long-term consequences of 
preterm birth on cardiovascular risk factors and bone mineral density. In this chapter, results from 
the studies described in this thesis are discussed, also in view of current literature. Subsequently, 
clinical implications and conclusions are presented and directions for future research are given. 
PART 1. SMALL FOR GESTATIONAL AGE
Factors associated with GH-induced growth response
GH-induced growth response is highly variable in short SGA children. It was suggested that higher 
pre-treatment insulin levels, assumedly reflecting lower insulin sensitivity, would lead to a lower 
growth response to GH treatment (1). In addition, it has been suggested that SGA children who 
are more insulin resistant before start of GH treatment, have a higher risk of glucose intolerance, 
which, in combination with a lower GH-induced growth response, could be considered a warning 
against treatment (2). In Chapter 2 we demonstrated, in 76 short SGA children, that it is not 
the degree of insulin sensitivity or ß-cell function, measured by a modified intravenous glucose 
tolerance test, but higher fasting serum insulin levels and a smaller increase in insulin levels that 
lead to a lower growth response during 6 months of GH treatment. No correlations were found 
between fasting insulin levels and measured insulin sensitivity, indicating that fasting insulin 
levels are no accurate proxy for insulin sensitivity in short children born SGA. Fasting insulin 
levels were, however, strongly related with overnight GH levels, which is also shown in in vitro 
studies (3), suggesting that not insulin, but pre-treatment overnight GH levels influence the GH-
induced growth response.
 It has been postulated that a higher GH dose would result in higher insulin levels due 
to a larger reduction in insulin sensitivity, and could be considered a reason not to treat short 
SGA children with GH if they have a low insulin sensitivity prior to start of GH treatment (2). 
We showed that GH treatment did result in a decrease in insulin sensitivity but, since insulin 
secretion simultaneously increased, the degree of glucose homeostasis remained unchanged. 
Furthermore, no differences in fasting insulin levels, insulin sensitivity and ß-cell function were 
found between subjects receiving 1 mg or 2 mg GH/m2/day. 
Conclusions, clinical implications, and directions for future research
Based on our findings, we conclude that higher pre-treatment insulin levels were associated with 
a lower growth response during GH treatment. Higher insulin levels were, however, not indicative 
for lower insulin sensitivity or less ß-cell function and might, therefore, not be considered a 
contraindication for GH treatment in short SGA children. However, based on the lower growth 
response, expectations on the degree of catch-up growth in such patients should not be too high, 
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and a higher GH dose might be needed to achieve an adult height within the normal range. We 
showed that a higher GH dose was not associated with a more adverse metabolic outcome than 
a lower dose.
 We also showed a strong relationship between pre-treatment overnight GH levels and 
fasting insulin levels in short SGA children. Further research is, however, needed to define this 
relationship in more detail.  
Health profile after discontinuation of GH treatment
GH treatment in short children born SGA induces catch-up growth and increases adult height 
(4-6), but it is also accompanied by a reduction in several risk factors for cardiovascular disease 
which are consistent with the lipolytic and anabolic properties of GH (7,8). GH, however, also has 
well-documented insulin-antagonistic effects and its use has been associated with a reduction 
in insulin sensitivity and an increase in insulin levels (9-12). Over recent years, concerns have 
been expressed regarding the long-term effects of GH treatment on increasing the risk for type 2 
diabetes and cardiovascular disease, but despite the fact that biosynthetic GH has been used for 
more than 25 years, there were no data available on the long-term effects after discontinuation 
of treatment in subjects born SGA. 
In Chapter 3 we describe a cross-sectional study in 377 young adults, investigating the long-
term impact of GH treatment on body composition and fat distribution, more than 6 years after 
its discontinuation. We showed that body composition of previously GH-treated adults was 
similar to that of untreated SGA adults with short stature, and that fat mass and fat distribution 
of previously GH-treated SGA subjects were also similar to those of SGA adults who showed 
spontaneous catch-up growth. These data are reassuring, as they suggest that long-term GH 
treatment of short SGA children does not have an unfavourable effect on body composition in 
young adulthood.  
 The beneficial effects on body composition during GH treatment were, unfortunately, no 
longer present. It has been suggested that the adverse effects of poor intrauterine growth on 
adipose tissue is most prominent in the first years of life. A previous study showed that girls 
born SGA, aged 2-8 years, tended to follow an altered developmental trajectory that may lead 
to an abnormal fat storage in puberty and adulthood (13). It could, therefore, be that the loss 
of beneficial effects of GH treatment on body composition, many years after its discontinuation, 
might be due to the fact that GH treatment was not started in the early years of life, but around 
8 years of age. Nowadays, some studies start GH treatment in (much) younger SGA children. 
It would be interesting to evaluate whether these children have a different adipose tissue 
development, particularly on the long term. 
 All SGA young adults, also those who did not receive GH treatment, had a lower lean body 
mass and tended to have a higher fat mass than healthy AGA controls, suggesting that SGA adults 
in general may have a different body composition than healthy controls. 
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Although the cross-sectional data described in Chapter 3 are reassuring, we cannot determine 
the exact influence of GH on the body composition in these young adults because we did not 
randomize for GH treatment in subjects born SGA. It might be that body composition in young 
adulthood was already ‘programmed’ in childhood, regardless of GH treatment. Since the efficacy 
of GH treatment has been well established, such a randomized controlled trial was considered 
unethical. Longitudinal data after discontinuation of GH treatment can provide insight in the 
effects of GH withdrawal on body composition and other cardiovascular risk factors. 
We, therefore, longitudinally investigated changes in parameters of vascular and metabolic 
health, during the first 2 years after discontinuation of treatment in another cohort of 272 young 
adults (Chapter 4). Willemsen et al. previously described an increase in fat mass during the 
first 6 months after discontinuation of GH (14), but up until now no data were available on the 
years thereafter. We showed that fat mass continued to increase significantly until 2 years after 
stop of GH treatment. In addition, after an initial decrease, lean body mass returned to values 
comparable with stop of GH treatment. These changes in body composition are opposite to those 
occurring during treatment, i.e. a decrease in fat mass and an increase in lean body mass (7,8). 
 After an initial increase, blood pressure also returned to values comparable with stop of 
treatment. Since it has been shown in another cross-sectional cohort that blood pressure of SGA 
subjects, who had discontinued treatment for more than 6 years, was significantly lower than 
blood pressure of untreated SGA subjects with short stature (15), it might be that blood pressure 
continues to decrease beyond the period of 2 years. 
 We are the first to describe changes in lipid profile after discontinuation of GH treatment 
and showed that the lipid profile changed unfavourably. Nevertheless, previously GH-treated 
SGA subjects continued to have a more beneficial lipid profile compared to untreated SGA 
subjects with short stature. 
Next to long-term effects of GH on risk factors for cardiovascular diseases, like body composition, 
lipid levels and blood pressure, we also studied the longitudinal changes in insulin sensitivity and 
β-cell function after discontinuation of GH treatment in 93 subjects born SGA until 5 years after 
stop of treatment (Chapter 5). In addition, we compared their data cross-sectionally at 5 years 
with those of 34 untreated SGA subjects and 44 healthy controls. 
 Our data show that after an initial increase after discontinuation of GH treatment, which is 
in line with previous reports (14,16), insulin sensitivity and ß-cell function remained unchanged 
in the years thereafter. At 5 years after discontinuation, glucose homeostasis of previously GH-
treated SGA subjects was similar to that of healthy AGA controls. These results are reassuring 
and confirm our previous cross-sectional data (15). 
 In addition, discontinuation of GH treatment was associated with a significant increase in 
fat percentage and total body fat mass, which, however, did not lead to a significant decrease in 
insulin sensitivity. 
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Conclusions, clinical implications, and directions for future research 
Based on the findings presented in Chapters 3, 4 and 5 we conclude that body composition and 
glucose homeostasis of young adults previously treated with GH were largely similar to those 
of untreated SGA adults. Glucose homeostasis of previously GH-treated SGA adults was even 
similar to that of healthy AGA controls, indicating that GH does not seem to have unfavourable 
effects on various risk factors for cardiovascular disease and type 2 diabetes in young adulthood. 
 Discontinuation of GH treatment in SGA subjects, however, leads to significant changes in 
body composition and lipid levels, reflecting the loss of the anabolic and lipolytic properties of 
GH. The increase in fat mass highlights the importance to ensure more awareness to lifestyle and 
healthy diet in subjects who are treated with GH. Reassuringly, despite the significant increase in 
fat percentage and total body fat mass, the results of previously GH-treated SGA subjects were 
similar to those of untreated SGA-S subjects.   
 Recently, the French SaGhE study suggested that there might be an increased overall and 
cardiovascular mortality in adults treated with GH during childhood for isolated GH deficiency 
(17). It is, however, unknown whether these subjects were diagnosed with adult GH deficiency 
after discontinuation of GH treatment and whether or not GH treatment was continued in these 
subjects. It might be that they found an increased mortality rate due to lack of adult GH treatment 
in GH deficient patients, rather than due to GH treatment during childhood. The Belgian, Swedish 
and Dutch part of the SaGhE study reported no deaths due to cancer or cardiovascular disease 
(18). These studies highlight the importance of evaluating detailed long-term effects of GH 
treatment. 
 Based on our data we can conclude that GH does not negatively influence risk factors for 
cardiovascular disease and type 2 diabetes later in life. The 5-year duration of our follow-up 
studies is, however, too short to conclude on the lifetime risk of cardiovascular disease and type 
2 diabetes. It is, therefore, important to continue to investigate the health profile of previously 
GH-treated subjects later in life, because the development of cardiovascular disease and type 2 
diabetes might occur later in life.
PART 2. PREMATURITY
Preterm birth and risk for cardiovascular disease
Chapter 6 and 7 describe associations of preterm birth and postnatal growth with risk factors 
for cardiovascular disease. Both preterm birth and poor fetal growth can lead to small size at 
birth. Most studies focus on subjects with a low birth weight and did not have information 
on gestational age, did not correct for it, or only included subjects born term (19-22). It was, 
therefore, difficult to determine whether the effect of a small size at birth on cardiovascular risk 
factors in later life was due to a small size for gestational age (SGA) or due to prematurity. 
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In Chapter 6 we demonstrate, in a cohort of 455 young adults, that those born preterm had a 
significantly higher percentage of total fat mass, trunk fat mass, and limb fat mass than subjects 
born term, but a relatively favourable lipid profile. 
 Our results are in line with previous results in a cohort of healthy young adults (23,24). 
It might well be that, under the influence of hormonal changes in puberty and adolescence, 
preterm subjects undergo a relatively large increase in fat mass. Further longitudinal follow-up 
studies in childhood and adolescence are important to confirm these findings.
 Because we showed that young adults born preterm had more fat mass, we expected a 
more adverse lipid profile. In contrast, a shorter gestational age was associated with lower Lp(a) 
levels and higher ApoA-I levels, and subjects born preterm had a significantly lower prevalence 
of adverse ApoA-I levels, compared with those born term. This might indicate that young adults 
born preterm have a more favorable lipid profile than those born term, although their body 
composition is less advantageous. Noteworthy, Lp(a) and ApoA-I levels are the only lipids not 
influenced by adult weight SDS, indicating that these levels are not directly influenced by fat or 
fat accumulation but are determined by other variables, like genetic factors (25-27).
 Our study was performed in young adults, while clinical manifestations of cardiovascular 
disease do usually not occur before middle age. Assuming that the amount of fat mass of preterm 
subjects remains higher throughout adulthood, they are expected to develop a more adverse 
lipid profile at a later age.
In Chapter 7 we demonstrate that preterm birth is associated with higher systolic blood pressure, 
independent of birth weight SDS. In contrast, we report a lower diastolic blood pressure in young 
adults born preterm which, however, contributed to a higher pulse pressure (28). In addition, 
we found a higher blood pressure variability and heart rate in subjects born preterm, which 
might be due to an altered sympathoadrenal function (29). These results are in line with those 
of others (29-33). In order to determine whether the associations of gestational age with CVD 
risk factors can be ascribed to small for gestational age (SGA) birth, we additionally performed 
subgroup comparisons. These comparisons showed significant differences in blood pressure, 
pulse pressure, and blood pressure variability, between the preterm subjects and AGA controls, 
which was irrespective of SGA birth. Because the prevalence of preterm birth and the survival 
rate is rapidly increasing, our results are of clinical relevance for an increasing number of subjects 
and thus of major importance for public health (34).   
Conclusions, clinical implications, and directions for future research
Based on the findings presented in Chapters 6 and 7, we conclude that preterm birth affects 
several determinants of cardiovascular disease, indicating that young adults born preterm might 
have increased risk for developing cardiovascular disease in later life, which is not due to being 
born SGA. This was confirmed by a recent study reporting increased cardiovascular mortality in 
subjects born preterm (35).
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To date, most long-term follow-up studies have focused on neurodevelopmental and respiratory 
complications of preterm infants, with little attention for cardiovascular outcome. Since the 
survival of preterm and very low birth weight infants has significantly improved, it is of increasing 
importance to assess the long-term effects of prematurity on determinants of cardiovascular 
diseases. 
 Our study population consisted of subjects without serious postnatal complications and 
did not include extremely preterm born subjects. Thus, whether our results can be generalized 
to subjects with complications, such as those with bronchopulmonary dysplasia, requires further 
research. 
 The duration of follow-up in our study is too short to definitely conclude on the risk of 
cardiovascular disease. The development of cardiovascular disease and type 2 diabetes is age-
dependent. Further research is, therefore, needed to evaluate whether or not these differences 
predispose subjects born preterm to cardiovascular diseases later in life. 
Preterm birth and bone mineral density
In Chapter 8 we studied the effect of prematurity on bone mineral density in early adulthood. 
Bone mineral density in later life depends largely on the peak bone mass achieved in early 
adulthood and the subsequent bone loss (36). A high peak bone mass provides a larger reserve 
later in life (36,37). Recent data show that peak bone mass is attained by the mid-twenties (38), 
around the age of our young adult cohort. Osteoporosis is an increasing cause of morbidity and 
mortality in the developed countries. It is characterized by low bone mass, deterioration of 
bone tissue and disruption of bone architecture, compromised bone strength and an increased 
fracture risk (39). Since early prevention of osteoporosis is likely to be more successful than 
treatment of an already established disorder, it is essential to identify potential risk factors.
 We showed no differences in bone mineral density between young adults born preterm or 
term. These results are in line with those of others (40,41). Another study showed that preterm 
born adolescents had a lower bone mineral content than those born at term. However, after 
correction for adult height and weight, these differences disappeared, indicating that the effect 
of gestational age on bone mineral density was largely influenced by adult body size (42). 
Conclusions, clinical implications, and directions for future research
Our data show that preterm birth is not associated with a lower bone mineral density in young 
adulthood, which is of major importance as an increasing number of preterm born subjects 
reach adulthood. Instead, adult weight, lean body mass and total body fat mass were important 
determinants of bone mineral density in young adulthood, indicating that it is important to 
ensure appropriate growth and nutrition throughout childhood and adolescence. Although our 
data are reassuring, there is no guarantee that bone mineral density will remain normal when 
subjects become older. Thus long-term follow-up is still warranted. 
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Our study comprises a relatively healthy population as extremely prematurely born subjects 
and those with a complicated neonatal period were excluded. Thus, whether our results can 
be generalized to subjects born very preterm or those with complications requiring e.g. 
dexamethasone treatment for bronchopulmonary dysplasia, requires further research.  
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GENERAL CONCLUSIONS
In the present thesis we describe the influence of several metabolic parameters on the variability 
in growth response to GH treatment and found that higher pre-treatment insulin levels were 
associated with a lower growth response during GH treatment. Higher pre-treatment insulin 
levels were, however, not indicative for lower insulin sensitivity or less β-cell function during GH 
treatment, and might, therefore, not be considered a contraindication for GH treatment in short 
SGA children. 
 We also describe longitudinal changes in several determinants for cardiovascular disease 
and type 2 diabetes until more than 6 years after discontinuation of GH in previously GH-treated 
SGA subjects. Figure 1 presents an overview of the results of this thesis and those previously 
reported by our research group. Based on these data, we conclude that GH has no unfavourable 
effects on body composition and glucose homeostasis in young adulthood. Discontinuation of GH 
treatment in subjects born SGA does, however, leads to significant changes in body composition 
and lipid levels, reflecting the loss of the anabolic and lipolytic properties of GH. 
 In addition, we report the long-term effect of prematurity on several parameters for 
vascular diseases and bone mineral density in young adulthood. Figure 2 summarizes the most 
important recent findings in young adults born preterm by our research group. Based on the 
data described in this thesis, we conclude that preterm birth affects several determinants of 
cardiovascular disease, indicating that young adults born preterm might have increased risk 
for developing cardiovascular disease in later life. Prematurity had no effects on bone mineral 
density in young adulthood. 
 It remains important to perform follow-up studies in previously GH-treated SGA subjects 
and in subjects born preterm, because development of cardiovascular disease and type 2 
diabetes is age-dependent and might occur later in life, beyond young adulthood.
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Figure 1. Follow-up studies in previously GH-treated subjects born SGA
!
GH treatment    Adult height     6 mo     1 yr     2 yr     3 yr     4 yr     5 yr     6 yr     7 yr  
Van Pareren et al.  
Breukhoven et al. (this thesis) 
Van Dijk et al.  
Willemsen et al.  
Breukhoven et al. (this thesis) 
Breukhoven et al. (this thesis) 
Si          (OGTT) 
BP    unchanged  
TC/HDL unchanged 
Si   (FSIGT) 
Fat%    
LBM   
Si  ~ AGA controls 
FM   
LBM   (temporarily) 
BP   (temporarily) 
Unfavourable change in lipid profile
Si  over the first 6 months and remains unchanged thereaer 
Si at 5 years aer stop ~ AGA controls  
FM  
FM at 5 years aer stop ~ AGA controls   
Si  ~ untreated short SGA 
BP < untreated short SGA 
 
 
S
T
O
P 
BC ~ untreated short SGA 
BC SGA ≠ AGA  
SGA: small for gestational age, AGA: appropriate for gestational age, OGTT: oral glucose tolerance test, FSIGT: 
frequently sampled intravenous glucose tolerance test, Si: insulin sensitivity, BP: blood pressure, LBM: lean body 
mass, BC: body composition, TC: total cholesterol, HDL: high density lipoprotein cholesterol  
→ longitudinal study, ↓ cross-sectional study
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Figure 2. Effects of preterm birth in young adulthood
Willemsen et al.   
  
Kerkhof et al.  
Breukhoven et al. 
 
   
    
   
  
     
   
 
  
  
Insulin sensivity
 Not associated with lower insulin sensivity 
Postnatal weight gain
 Accelerated gain in weight relave to length 
 during the period from birth to term age, as 
 well as during the first three months of life, 
 has adverse effects on body composion in 
 early adulthood
 Rapid weight gain aer term age is an    
 important determinant of body composion in 
 later life 
Gonadal funcon
 No effect on gonadal funcon in men
 No effect on follicle pool size in women
Bone mineral density
 Lower bone mineral density 
Parameters for cardiovascular disease
 More fat mass
 Relavely favourable lipid profile
 Higher systolic blood pressure, pulse pressure, 
 blood pressure variability and heart rate, and a 
 lower diastolic blood pressure
 No effect on pulse wave velocity and arod 
inma media thickness
 Not associated with combined biomarkers    
 related to early stage atherosclerosis 
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Chapter 1
This chapter provides a general introduction in the definitions, prevalence and possible causes 
of SGA birth. Furthermore, clinical and endocrinological aspects associated with SGA birth are 
described, such as short stature, the GH-IGF-IGFBP axis, and cardiovascular disease and type 2 
diabetes. This chapter also gives a summary of previously described effects of GH on growth, 
the GH-IGF-IGFBP axis, body composition and risk factors for cardiovascular disease and type 
2 diabetes. In addition it gives a general introduction in preterm birth and the associations 
between preterm birth and cardiovascular disease and bone mineral density. Finally, the aims of 
the studies performed and the outline of this thesis are presented.
Chapter 2
GH treatment induces catch-up growth and increases adult height in short children born SGA, but 
the growth response is variable. It has been suggested that higher pre-treatment insulin levels, 
assumedly reflecting lower insulin sensitivity, lead to a lower growth response to GH treatment. 
In the study described in chapter 2, we aimed to investigate whether the growth response during 
6 months of GH treatment was related to baseline fasting insulin levels, insulin sensitivity and 
ß-cell function and to assess whether insulin levels could serve as a proxy for insulin sensitivity 
in short children born SGA. In this prospective study, using data of 76 prepubertal short children 
born SGA, we showed that higher pre-treatment insulin levels were associated with a lower 
growth response during GH treatment. They were, however, not indicative for lower insulin 
sensitivity or less β-cell function during GH treatment. Based on our findings, we concluded that 
high insulin levels might not be considered a contraindication for GH treatment in short SGA 
children. 
Chapter 3
GH treatment of short children born SGA results in a decline in fat mass and an increase in 
lean body mass. It was, however, unknown whether these changes persist into adulthood 
after cessation of GH. We, therefore, cross-sectionally investigated body composition and fat 
distribution, measured by dual-energy X-ray absorptiometry in 377 young adults. Fifty-nine 
previously GH-treated SGA subjects were compared to 52 untreated SGA subjects with short 
stature, 161 SGA adults with spontaneous catch-up growth, and 105 healthy normal-statured 
controls born appropriate for gestational age. Fat mass and fat distribution of previously GH-
treated SGA subjects were not significantly different from those of untreated SGA subjects 
with short stature and those with spontaneous catch-up growth, at more than 6 years after 
discontinuation of GH treatment. All SGA subgroups had a lower lean body mass and tended to 
have a higher fat mass than healthy controls. We, therefore, concluded that GH-induced catch-
up growth does not have unfavourable effects on fat mass and fat distribution compared with 
spontaneous catch-up growth. However, young adults born SGA in general have a different body 
composition than young adults born appropriate for gestational age. 
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Chapter 4
GH treatment induces a decrease in fat mass and blood pressure, and an increase in lean body 
mass, which is consistent with the lipolytic and anabolic properties of GH. Only limited data 
were available on the longitudinal changes after discontinuation of GH treatment. We, therefore, 
longitudinally investigated changes in body composition, lipid levels and resting blood pressure, 
until 2 years after discontinuation of GH treatment, in 101 subjects born SGA. Fat mass increased 
significantly over the first 2 years after stop of GH treatment and lean body mass temporarily 
decreased. Overall, the lipid profile showed an adverse change after discontinuation of GH 
treatment. In addition, after a temporarily increase in the first 6 months, blood pressure at 2 years 
after discontinuation of GH was comparable to levels at stop. We concluded that discontinuation 
of GH treatment in subjects born SGA leads to significant adverse changes in body composition 
and several metabolic parameters which continue for at least 2 years after discontinuation, 
reflecting the loss of GH properties.
Chapter 5
SGA birth has been associated with an increased risk of developing type 2 diabetes. It is known 
that GH treatment reduces insulin sensitivity, but no data were available on the long-term 
effects of GH treatment on insulin sensitivity and β-cell function after its cessation. Therefore, 93 
previously GH-treated SGA adults were followed longitudinally until 5 years after discontinuation 
of GH treatment. Data at 5 years were compared with those of 34 untreated SGA adults with 
short stature, and 44 healthy controls. Insulin sensitivity was assessed by frequently sampled 
intravenous glucose tolerance tests and body composition by dual-energy X-ray absorptiometry. 
 We showed that after an initial increase after discontinuation of GH treatment, insulin 
sensitivity and β-cell function remain unchanged in the years thereafter. At 5 years after 
discontinuation of GH treatment, glucose homeostasis of previously GH-treated SGA subjects 
was similar to that of healthy AGA controls, which is reassuring. Discontinuation of GH treatment 
was, however, associated with a significant increase in fat percentage and total body fat mass.
 
Chapter 6
Associations between small size at birth and abnormal cardiovascular parameters in later life 
have been reported. It was, however, unknown whether the effects of a small size at birth 
on cardiovascular risk factors in later life was due to a small size for gestational age or due to 
prematurity. We, therefore, aimed to investigate the long-term effects of preterm birth on lipid 
levels and fat mass in early adulthood. We conducted a cross-sectional study in 455 healthy 
subjects, aged 18 to 24 years; 167 preterm subjects were compared with 288 full-term subjects. 
Young adults born preterm had a significantly higher percentage of total fat mass, trunk fat 
mass and limb fat mass than those born term. Furthermore, young adults born preterm had 
significantly lower serum lipoprotein a levels and higher apolipoprotein A-I levels than those 
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born term. Multiple linear regression analyses to assess the association between gestational 
age and fat mass and lipid levels showed similar results. Based on these results, we concluded 
that preterm birth is associated with more total fat mass, trunk fat, and limb fat mass in early 
adulthood, but also with a relatively favorable lipid profile.
Chapter 7
Both preterm birth and small birth size for gestational age have been associated with increased 
risk for cardiovascular disease, but controversies still existed. In the study described in Chapter 
7, we aimed to investigate the effect of preterm birth on risk factors for cardiovascular disease, 
independent of birth size. In the study, using data of 406 young adults, we showed that preterm 
birth is associated with higher systolic blood pressure, pulse pressure, blood pressure variability, 
and heart rate, and with lower diastolic blood pressure in early adulthood, also after adjustment 
for confounders including size at birth. We, therefore, concluded that young adults born preterm 
might have a higher risk of cardiovascular disease than those born at term, independent of 
birth size. There was no effect of gestational age on pulse wave velocity and carotid intima-
media thickness, which is a marker of early stage atherosclerosis, but our study population is still 
relatively young, and it might well be that this effect will arise at an older age. 
Chapter 8
Previous studies showed conflicting data on the effect of prematurity on bone mineral density in 
infants and children and only limited data were available on the long-term effects of prematurity 
on bone mineral density in early adulthood. We, therefore, cross-sectionally investigated bone 
mineral density, measured by dual-energy X-ray absorptiometry, in 276 healthy subjects, aged 
18-24 years (151 preterm subjects and 125 subjects born at term). Gestational age was not 
associated with bone mineral density of the total body and lumbar spine, also after adjustment 
for possible confounders. No significant differences were found between young adults born 
preterm or term. We concluded that preterm birth without serious postnatal complications is 
not associated with a lower bone mineral density in young adulthood.
Chapter 9
In this chapter, the main findings of the studies described in the present thesis are discussed, 
also in context of current literature. We emphasize on clinical implications and give suggestions 
for future research. 
Chapter 11
Samenvatting
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Hoofdstuk 1
Dit hoofdstuk geeft een algemene inleiding in de definities, de prevalentie en de mogelijke 
oorzaken van SGA geboorte. Bovendien worden de klinische en endocrinologische aspecten die 
samenhangen met SGA geboorte beschreven, zoals een kleine gestalte, de GH-IGF-IGFBP as, hart-
en vaatziekten en type 2 diabetes. In dit hoofdstuk wordt ook een samenvatting gegeven van 
eerder beschreven effecten van GH op de groei, de GH-IGF-IGFBP as, de lichaamssamenstelling 
en risicofactoren voor hart-en vaatziekten en type 2 diabetes. Daarnaast geeft dit hoofdstuk een 
algemene inleiding in allerlei aspecten van prematuriteit en wordt er ingegaan op de associaties 
tussen prematuriteit en hart-en vaatziekten en botdichtheid. Aan het einde van dit hoofdstuk 
worden de doelstellingen van de studies en de inhoud van dit proefschrift besproken.
Hoofdstuk 2
GH behandeling induceert inhaalgroei en zorgt voor een betere volwassen lengte in te kleine SGA 
kinderen, maar de groeirespons is variabel. Er is gesuggereerd dat hogere insulinespiegels voor 
start van de behandeling, vermoedelijk als gevolg van een lagere insulinegevoeligheid, leiden 
tot een lagere groeirespons op GH behandeling. In de studie beschreven in hoofdstuk 2 hebben 
we onderzocht of de groeirespons gedurende de eerste 6 maanden van de GH behandeling 
was gerelateerd aan nuchtere insulinespiegels, insulinegevoeligheid en ß-cel functie voor de 
start van de behandeling. Daarnaast hebben we onderzocht of insulinspiegels kunnen dienen 
als maat voor de insulinegevoeligheid in te kleine SGA kinderen. In deze prospectieve studie 
in 76 prepuberale SGA kinderen bleken hogere insulinespiegels geassocieerd met een lagere 
groeirespons tijdens GH behandeling. Hoge insulinespiegels waren echter geen maat voor 
een lagere insulinegevoeligheid of slechtere ß-cel functie tijdens de GH behandeling. Wij 
concludeerden daarom dat hoge insulinespiegels voor de start van de behandeling niet mogen 
worden beschouwd als een contra-indicatie voor GH behandeling in te kleine SGA kinderen.
Hoofdstuk 3
GH behandeling in te kleine SGA kinderen resulteert in een daling van de vetmassa en een 
toename van de spiermassa. Het was echter niet bekend of deze veranderingen aanhouden tot 
de volwassen leeftijd. Wij hebben daarom de lichaamssamenstelling en vetverdeling, gemeten 
met behulp van een dual-energy X-ray absorptiometry, onderzocht in 377 jong volwassenen; 
59 SGA jong volwassenen die in het verleden behandeld waren met GH werden vergeleken 
met 52 onbehandelde SGA jong volwassen met een kleine gestalte, 161 SGA jong volwassenen 
met spontane inhaalgroei, en 105 gezonde controles. Vetmassa en vetverdeling van de GH-
behandelde groep waren niet significant verschillend van die van de andere 2 SGA subgroepen, 
op meer dan 6 jaar na het stoppen van de GH behandeling. Alle SGA subgroepen hadden een 
lagere spiermassa en een trend tot een hogere vetmassa dan gezonde jong volwassenen. Wij 
concludeerde daarom dat GH-geïnduceerde inhaalgroei geen ongunstige effecten heeft op de 
vetmassa en vetverdeling in vergelijking met spontane inhaalgroei. Onze studie liet echter zien 
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dat alle SGA jong volwassenen mogelijk een andere lichaamssamenstelling hebben dan gezonde 
jong volwassenen.
Hoofdstuk 4
GH behandeling resulteert in een afname van de vetmassa, een verlaging van de bloeddruk en een 
toename van de spiermassa, in overeenstemming met de lipolytische en anabole eigenschappen 
van GH. Er waren echter maar weinig gegevens beschikbaar over de veranderingen hiervan na 
staken van de GH behandeling. Wij hebben daarom, in 101 jong volwassenen, gekeken naar 
de lichaamssamenstelling, het lipidenprofiel en de bloeddruk, gedurende 2 jaar na het stoppen 
van de GH behandeling. De vetmassa nam significant toe en de spiermassa nam tijdelijk af. Het 
lipidenprofiel toonde een nadelige verandering na het stoppen van de GH behandeling. Na een 
tijdelijke stijging, daalde de bloeddruk weer tot hetzelfde niveau als direct na het staken van de 
behandeling. Wij concludeerden dat staken van de GH behandeling in jonge SGA volwassenen 
leidt tot aanzienlijke veranderingen in de lichaamssamenstelling en een aantal metabole 
parameters, welke het gevolg zijn van het verlies van de eigenschappen van GH.
Hoofdstuk 5
SGA geboorte is in verband gebracht met een verhoogd risico op het ontwikkelen van type 2 
diabetes. Het is bekend dat GH behandeling de gevoeligheid voor insuline vermindert, maar 
er waren geen gegevens beschikbaar over de lange-termijn effecten van GH behandeling op 
insulinegevoeligheid en β-cel functie. Daarom werden 93, voorheen met GH behandelde, SGA 
volwassenen longitudinaal gevolgd tot 5 jaar na het staken van de behandeling. Gegevens op 5 
jaar na stop werden vergeleken met de gegevens van 34 onbehandelde SGA geboren volwassenen 
met een te kleine gestalte, en 44 gezonde controles. De insulinegevoeligheid werd gemeten met 
behulp van een zogenaamde ‘frequently sampled intravenous glucose tolerance test’ en de 
lichaamssamenstelling met behulp van een dual-energy X-ray absorptiometry. Wij toonden aan 
dat na een aanvankelijke stijging in de eerste maanden na het staken van de GH behandeling, 
de insulinegevoeligheid en β-cel functie onveranderd blijven in de jaren daarna. Vijf jaar na het 
staken van de GH behandeling was de glucosehuishouding van de eerder met GH behandelde 
SGA volwassenen vergelijkbaar met die van gezonde AGA controles. Dit is geruststellend. 
Staken van de GH behandeling was echter geassocieerd met een significante toename van het 
vetpercentage en de totale vetmassa. 
Hoofdstuk 6
In het verleden zijn er associaties gemeld tussen klein zijn bij de geboorte en abnormale 
cardiovasculaire parameters op latere leeftijd. Het was echter niet bekend of de associaties 
tussen klein zijn bij de geboorte en cardiovasculaire risicofactoren het gevolg waren van SGA 
geboorte of van prematuriteit. In 455 gezonde jong volwassenen met een leeftijd tussen de 18 
en 24 jaar, onderzochten wij de lange termijn effecten van prematuriteit op de lipidenspiegels 
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en de vetmassa. 167 prematuur geboren jong volwassenen werden vergeleken met 288 à term 
geboren jong volwassenen. Prematuur geboren jong volwassenen hadden significant hogere 
percentages totale vetmassa, romp vetmassa en vetmassa van de ledematen in vergelijking met 
jong volwassenen die à term waren geboren. Wel hadden prematuur geboren jong volwassenen 
significant lagere serum lipoprotein a spiegels en hogere apolipoproteïne AI spiegels dan de à 
term geboren jong volwassenen. Multipele lineaire regressie-analyses om de associatie tussen 
zwangerschapsduur en de vetmassa en lipiden spiegels te beoordelen toonde vergelijkbare 
resultaten. Op basis van deze resultaten concludeerden wij dat prematuriteit is geassocieerd 
met meer totale vetmassa en meer romp vet en vet op de ledematen, maar met een relatief 
gunstig lipidenprofiel.
Hoofdstuk 7
Premature geboorte en te klein zijn bij de geboorte voor de zwangerschapsduur (SGA) veroorzaken 
beide een laag geboortegewicht. Verschillende studies hebben een relatie aangetoond tussen een 
laag geboortegewicht en een verhoogd risico op hart- en vaatziekten. Echter, tot op heden was de 
invloed van premature geboorte op deze relatie onbekend. In hoofdsuk 7 beschrijven we de studie 
waarin we de associatie hebben onderzocht tussen premature geboorte/zwangerschapsduur en 
verschillende risicofactoren voor hart- en vaatziekten op jong volwassen leeftijd, ongeacht het 
geboortegewicht. In deze studie hebben we laten zien dat premature geboorte geassocieerd 
is met een hogere systolische bloeddruk, polsdruk, bloeddrukvariabiliteit, hartslag en met een 
lagere diastolische bloeddruk. De resultaten bleven gelijk na correctie voor geboortegewicht 
en geboortelengte. Onze conclusie was dat prematuur geboren jong volwassenen mogelijk een 
hoger risico hebben op hart- en vaatziekten dan a term geboren jong volwassenen en dat dit 
onafhankelijk is van de grootte bij de geboorte. We vonden geen effect van zwangerschapsduur 
op de Pulse Wave Velocity (meting van de arteriele stijfheid) en de intima media dikte van de 
arteria carotis op jong volwassen leeftijd, maar onze studiepopulatie is nog relatief jong en het 
kan zijn dat deze associatie ontstaat op een latere leeftijd. 
Hoofdstuk 8
Eerdere studies laten tegenstrijdige resultaten zien wat betreft het effect van prematuriteit op 
het botdichtheid bij zuigelingen en kinderen. Er zijn slechts beperkte gegevens beschikbaar 
over de lange-termijn effecten van prematuriteit op de botdichtheid op jong volwassen 
leeftijd. Wij hebben daarom de botdichtheid, gemeten met behulp van een dual-energy X-ray 
absorptiometrie, onderzocht in 276 gezonde proefpersonen in de leeftijd van 18 tot 24 jaar (151 
prematuur geboren proefpersonen en 125 à term geboren personen). Zwangerschapsduur was 
niet geassocieerd met de botdichtheid van het totale lichaam en de lumbale wervelkolom, ook 
niet na correctie voor mogelijke confounders. Er werden geen significante verschillen gevonden 
tussen de prematuur en à term geboren proefpersonen. Wij concludeerden dat prematuriteit, 
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zonder ernstige postnatale complicaties, niet is geassocieerd met een lagere botdichtheid op 
jong volwassen leeftijd.
Hoofdstuk 9
In dit hoofdstuk worden de belangrijkste bevindingen van de studies in dit proefschrift 
besproken, ook in context van de huidige literatuur. We bespreken de klinische implicaties en 
geven suggesties voor toekomstig onderzoek. 
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Ook wil ik graag alle kinderartsen hartelijk bedanken met wie ik de afgelopen jaren heb mogen 
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Sten, Erica, Gladys en Josine, dank jullie wel voor de gezelligheid en al jullie input tijdens de 
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Novo Nordisk B.V. Nederland wil ik graag bedanken voor de prettige samenwerking en de 
financiële ondersteuning van de studies en dit proefschrift. 
Ineke Beukers, bedankt voor al je hulp en advies de afgelopen jaren!
Prof. dr. E.P. Krenning wil ik bedanken voor de mogelijkheid die wij hebben gekregen om DXA-
scans te laten maken op de afdelinge nucleaire geneeskunde. Jopie Sluimer wil ik bedanken voor 
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Dr. M.A.J. de Ridder wil ik bedanken voor haar hulp en antwoorden op mijn statistische vragen. 
Dr. W.H. Hackeng wil ik hartelijk bedanken voor het bepalen van de insulines en glucoses en zijn 
altijd aanwezige interesse in onze onderzoeken. 
Alle (ex)onderzoekers uit het Sophia, hartelijk dank voor jullie gezelligheid, de koffietjes bij 
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Ralph, Roderick, Emile en Daniëlle. Dank voor jullie wetenschappelijke input, maar natuurlijk 
ook voor alle warmte en gezelligheid de afgelopen jaren. Manouk, heel veel plezier bij de IUGR-
2 studie. Gerthe en Judith, dankzij jullie heb ik een onvergetelijke tijd gehad bij de endo. Dank 
voor jullie steun, enthousiasme en gezelligheid de afgelopen jaren. Ik zal die keer dat jullie 
onverwachts met butter-chicken voor mijn voordeur stonden nooit vergeten! En Gerthe, lieve 
vriendin en paranimf, ik ben er super trots op dat je naast me staat! 
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gesprekken over van alles en nog wat, uitjes met of zonder de kids erbij. Ik geniet er intens van 
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TC total cholesterol
TG triglycerides
TH target height
